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Abstract 
Background
Worldwide the prevalence of hypertension is increasing rapidly, which calls for 
effective public health measures. Whether dairy intake could play a role in reducing 
population blood pressure is not yet clear. The objective of this thesis was to examine 
the association of dairy intake with blood pressure level and incident hypertension in 
the Dutch population, and to assess the blood pressure effect of two ‘promising’ dairy 
components, i.e. lactotripeptides (ipp and vpp) and cis-9, trans-11 conjugated linoleic 
acid (cla).
Methods
Intakes of total dairy and types of dairy were examined in relation to blood pressure level 
in 21,553 Dutch adults aged 20-65 y from the morgen study. The risk of hypertension 
was examined in 3454 of these participants with 5 y of follow-up and in 2245 older 
Dutch adults from the Rotterdam study with 6 y of follow-up. The blood pressure 
effect of lactotripeptides was assessed in an 8-week, randomized controlled trial in 135 
middle-aged Dutch subjects with elevated blood pressure. The effect of a high dose of 
cis-9, trans-11 cla on blood pressure was studied in a 9-week, randomized cross-over 
trial in 61 young, normotensive Dutch subjects.
Results
Blood pressure levels were not consistently related to overall dairy intake or intake of 
specific dairy foods in the general Dutch population (morgen study). Longitudinal 
analyses in the morgen study and the Rotterdam study showed a ~20% reduced risk of 
hypertension in subjects who consumed more than 150 mL (~1 serving) of low-fat dairy 
per day, whereas other dairy foods were not consistently associated with incident 
hypertension. Blood pressure was not affected by intervention with lactotripeptides. 
The mean difference (95% confidence interval) in systolic blood pressure response 
between the treatment and control group was 2.8 mm Hg (–2.6, 8.2) for lactotripeptides 
obtained by fermentation, –0.5 mm Hg (–6.0, 5.0) for lactotripeptides obtained by 
enzymatic hydrolysis, and 1.6 mm Hg (–3.9, 6.9) for synthetic lactotripeptides (p = 0.46). 
With regard to intervention with cis-9, trans-11 cla, systolic blood pressure changed 
–0.1 mm Hg (–1.49, 1.27) compared to control treatment (oleic acid), which was not 
statistically significant (p = 0.87).
Conclusion
The findings presented in this thesis suggest that low-fat dairy products may reduce 
the risk of hypertension. However, it should be noted that evidence has mainly been 
derived from observational studies and controlled intervention studies are needed to 
confirm these findings. With regard to dairy components, we conclude that 
lactotripeptides and cla are unlikely to play an important role in blood pressure 
regulation. Current dietary guidelines in countries like the us and the Netherlands 
include 2-3 servings of low-fat or fat-free dairy per day, which is mainly based on the 
prevention of osteoporosis by ensuring an adequate intake of calcium. Based on the 
findings presented in this thesis, and evidence from the scientific literature, there is at 
present no need to adapt these recommendations for the purpose of hypertension 
prevention. 
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Blood pressure and cardiovascular risk
Hypertension is an important public-health challenge worldwide. The definition of 
hypertension and classification of blood pressure levels is presented in Table 1.1. In 
2000, 25% of the world’s adult population had hypertension and this is expected to 
increase to 29% in 20251. In the Netherlands, around 75% of the adults have suboptimal 
blood pressures (i.e. 120/80 mm Hg or higher), comprising roughly 25% with 
hypertension, 25% with ‘high-normal’ blood pressure and 25% with ‘normal’ blood 
pressure (as defined in Table 1.1)2. Blood pressure is a strong, independent and 
modifiable risk factor for cardiovascular and renal diseases3. Systolic blood pressure 
nowadays is considered a more powerful predictor of clinical endpoints than diastolic 
blood pressure, especially after the age of 55 y4. There is no evidence for a threshold 
effect, i.e. the risk of cardiovascular morbidity and mortality increases from blood 
pressure levels as low as 115 mm Hg systolic upward5, 6. Suboptimal blood pressure is 
responsible for 54% of stroke and 47% of ischemic heart disease worldwide7; about half 
of this burden can be attributed to hypertension, and the remainder to lower levels of 
blood pressure. In view of the continuing epidemic of blood pressure-related diseases, 
effective public health approaches that lead to population-wide reductions in blood 
pressure are warranted even among those who do not have hypertension.
The worldwide prevalence of hypertension is increasing rapidly, which calls for effective public 
health measures throughout the entire range of blood pressure.
Dietary prevention strategies
It has been estimated that as much as 80% of cardiovascular events could be prevented 
by a healthy diet and lifestyle9, 10. International guidelines for the management of 
hypertension include lifestyle modifications for persons with high-normal blood 
Table 1.1 Definition of hypertension and classification of blood pressure levels1
Category Systolic blood  Diastolic blood
 pressure (mm Hg)  pressure (mm Hg)
Optimal
Normal2
High Normal2
Grade 1 (mild) hypertension3
Grade 2 (moderate) hypertension3
Grade 3 (severe) hypertension3
Isolated systolic hypertension3
<120
120-129
130-139
140-159
160-179
≥180
≥140
and
and/or
and/or
and/or
and/or
and/or
and
<80
80-84
85-89
90-99
100-109
≥110
<90
1 According to 2007 esh/esc guidelines on hypertension8. 
2  ‘Normal’ and ‘high normal’ combined are considered ‘prehypertension’      
according to 2003 jnc 7 guidelines on hypertension3.
3 Or use of antihypertensive medication.
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pressure and hypertension. Well-established dietary factors that lower blood pressure 
are weight reduction in overweight and obese individuals, reduced salt intake, 
moderation of alcohol consumption (among those who drink), and increased potassium 
intake11, 12. More recently, interest has shifted towards the total dietary pattern, rather 
than focusing on individual nutrients. A hallmark study in this respect is the Dietary 
Approaches to Stop Hypertension (dash) trial13. In this well-controlled feeding study, 
blood pressure in 459 untreated mildly hypertensive us individuals was substantially 
reduced by a diet that emphasized fruits, vegetables, and low-fat dairy products and 
contained less saturated fat (amongst other dietary modifications). Because of the 
multifactorial intervention, it is not clear to what extent the inclusion of (low-fat) dairy 
contributed to the ‘dash’ effect. us health authorities now recommend a dash-type 
dietary pattern, including 2-3 daily servings of low-fat dairy products as an effective 
non-pharmacological measure to lower blood pressure11.
Dietary prevention strategies are important for maintaining a healthy blood pressure. Whether 
intake of dairy products could play a role in reducing population blood pressure remains to be 
established.
Dairy and blood pressure: observational evidence 
Since the publication of the dash trial, the association of dairy intake with blood 
pressure and incident hypertension has been examined in different populations, both 
cross-sectionally14-18 and prospectively15, 19-25 (Table 1.2). In 7 out of 12 studies total dairy 
intake was inversely related to blood pressure or risk of hypertension14, 16, 17, 20, 21, 23, 25, 
whereas other studies did not show consistent associations for total dairy intake15, 18, 19, 
22, 24. Apart from chance, this may be attributed to heterogeneity of study populations 
(e.g. age, race, blood pressure level, overweight status), study design (cross-sectional, 
short-term prospective, and long-term prospective studies), classification and range of 
dairy intake, differences in ‘background’ diet, and correction for major confounders 
(e.g. dairy-related dietary factors, physical activity).
 
Little is known about the possible influence of dairy groups (e.g. low-fat dairy, high-fat 
dairy, fermented dairy) as well as individual dairy products (e.g. cheese, yogurt) on 
blood pressure. Most of the dairy products in the dash diet were in the form of 1% 
low-fat or fat-free milk (74%) and low-fat or fat-free yogurt (18%)26. Several observational 
studies reported findings separately for low-fat and high-fat dairy18-21, 24, 25 (Table 1.2). 
Three studies reported an inverse association for low-fat but not for high-fat dairy 
products19, 24, 25, whereas this was not confirmed by others18, 20, 21. In about half of the 
studies the association of specific products with blood pressure or hypertension was 
examined17, 18, 21-23, 25, but no consistent relationships emerged from these data. 
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Observational studies generally show inverse associations between dairy intake and blood 
pressure or hypertension, although findings are not conclusive. Little is known about specific 
types of dairy foods in relation to blood pressure.
Dairy and blood pressure: experimental evidence 
Intervention studies of dairy intake and blood pressure are scarce. Often cited in this 
respect is the above mentioned dash trial13. This study showed that blood pressure 
reductions were more pronounced when low-fat dairy products were added to a healthy 
fruits-and-vegetables diet (apart from other dietary changes). It should be emphasized, 
however, that the dash trial was not designed to assess the effect of single food groups. 
The role of dairy foods in blood pressure control can therefore not be established on 
basis of this trial. We identified 7 trials in which dairy formed part of the dietary 
intervention (Table 1.3). Of these, only 2 studies aimed to assess the effect of dairy per 
se on blood pressure, showing no clear beneficial effect27, 28. In a cross-over trial by 
Bierenbaum et al. dairy products (yogurt, cottage cheese, and milk) did not lower blood 
pressure compared to orange juice in 50 normotensive us men and women28. Barr et al. 
showed no effect on blood pressure of an increase of 3 glasses of low-fat milk per day 
in 204 normotensive us adults aged 55 y and over27. Other trials focused on components 
in a dairy matrix (e.g. minerals)29-32, or included dairy as part of a changed dietary 
pattern13. Dairy minerals (calcium, potassium, magnesium) were significantly shown to 
lower systolic blood pressure by 3 mm Hg in 60 normotensive Dutch subjects31. A high-
calcium diet by manipulating dairy intake, however, did not significantly lower blood 
pressure in 13 mildly untreated hypertensive us men30. In a randomized double-blind 
cross-over trial, a high-calcium milk enriched with potassium had a small hypotensive 
effect compared to skim milk or high-calcium skim milk in 38 healthy Caucasian adults 
aged 40 y and over29, whereas increasing the potassium content of skimmed milk by 
750 mg did not affect blood pressure in 113 mildly hypertensive subjects in a well-
controlled randomized trial by Van Mierlo et al.32.
Randomized controlled trials exclusively focusing on dairy are scarce and data are insufficient 
to draw conclusions.
Dairy components and blood pressure
Dairy products are a main source of calcium, accounting for about 70% of the total 
daily calcium intake in the Netherlands33. The importance of dietary calcium in the 
prevention and treatment of hypertension was first suggested in 198434 and has been 
examined extensively. Several meta-analyses of clinical trials showed that the effect of 
calcium on blood pressure is well-established, but relatively small with reductions in 
systolic blood pressure of 1-2 mm Hg for calcium doses of 400 to 2000 mg/d35-38. It has 
been suggested that the impact of calcium on blood pressure may be greater in persons 
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with a low habitual intake of dietary calcium37, 38. This would imply that in countries 
like the Netherlands, with an average intake of calcium of ~1000 mg/d33, there is little 
need to advocate higher calcium intakes to reduce population blood pressure. On the 
contrary, in countries with less calcium in the diet (e.g. us) recommendations to increase 
calcium via dairy intake may be more important for the prevention of hypertension39. 
When reviewing intervention studies on calcium and blood pressure, there seems to be 
greater consistency for calcium-rich foods than non-dietary calcium supplements37. 
This would emphasize the importance of the food matrix or total dietary pattern. 
Because vitamin D is important for calcium absorption, it has been suggested that the 
effect of calcium on blood pressure may depend on vitamin D status25, 40. Other minerals 
that are present in dairy foods have also been inversely related to blood pressure. Blood 
pressure reductions from 2 to 6 mm Hg systolic have been found in trials of potassium 
supplementation41-43 and weaker effects (~1 mm Hg systolic) have been found for 
supplemental magnesium39, 44. Apart from dairy minerals with a blood pressure lowering 
potential, dairy products (mainly cheese) also contain sodium which is a well-established 
risk factor for blood pressure11.
A relatively new line of research focuses on the blood pressure-lowering potential of 
milk-derived bioactive peptides, which are amino acid sequences with biological activity 
that are embedded in milk protein. A wide range of activities of these peptides have 
been described, including antihypertensive properties, immunomodulatory and opioid 
properties, enhancement of mineral absorption and localized effects on the gut45. Latent 
bioactive peptides can be released from protein during food processing, e.g. via 
fermentation of casein by Lactobacillus helveticus or enzymatic hydrolysis by Aspergillus 
oryzae protease. Fermented milks and casein hydrolysates have been shown to lower 
blood pressure in a number of trials in (mildly) hypertensive subjects, mainly from 
Japan and Finland46, 47. So far, reported results have been promising; two meta-analyses 
of randomized controlled trials showed a mean reduction in blood pressure of 5 mm 
Hg systolic and 2 mm Hg diastolic46, 47. However, results have not yet been confirmed in 
other populations. Inhibition of the angiotensin-converting enzyme (ace) has been 
proposed as an underlying mechanism for the blood pressure lowering effect of milk-
derived peptides. ace plays a key role in blood pressure regulation by generating the 
vasoconstricting angiotensin ii from angiotensin i, and inactivating bradykinin which 
is a vasodilator. Isoleucine-Proline-Proline (ipp) and Valine-Proline-Proline (vpp), two 
peptides from milk casein, are considered promising ace-inhibiting bioactive peptides. 
However, although ace-inhibiting properties of fermented milk or its peptides have 
been demonstrated in in vitro and animal models48, 49, recent data in humans suggest 
that the plasma concentration of ace-inhibiting peptides are far below the effective 
concentration for plasma ace-inhibition50. 
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Another dairy component that has recently attracted much attention is cis-9, trans-11 
conjugated linoleic acid (cla). Cis-9, trans-11 cla is produced in the rumens of cows, 
sheep and other ruminant animals through partial hydrogenation of unsaturated fatty 
acids from the feed by bacteria. It can also be formed from vaccenic acid in animals and 
in humans51. It is consumed by humans in foods and as supplements. In general, 
supplements consist of 50:50 mixtures of the isomers cis-9, trans-11 cla and trans-10, 
cis-12 cla or mixtures of more isomers. cla in dairy products consists of over 90% of 
the cis-9, trans-11 cla isomer, although absolute amounts are small. Favorable effects of 
cla on health, for example weight reduction, insulin sensitivity and blood lipid profiles 
have been reported in animal studies52. In addition, cla was found to lower blood 
pressure in several rat models53-55. On the other hand, cla is a trans fatty acid and 
harmful effects in the cardiovascular system cannot be excluded. Little is known about 
the effect of cla on human blood pressure.
There are several hypotheses on how dairy may lower blood pressure, but the underlying 
mechanisms are largely unknown. Calcium is considered the main antihypertensive component 
in dairy, although its effect is relatively small. Two dairy components that have recently 
attracted much attention are lactotripeptides (ipp and Vpp) and cis-9, trans-11 conjugated 
linoleic acid (CLa). Their role in blood pressure regulation, however, has not been established.
Dairy intake in the Netherlands
The Netherlands is a country with a relatively high average dairy intake from a wide 
variety of products. Dairy products form part of the Dutch traditional diet and 70-80% 
is consumed at home33. Around 75% is consumed at three fixed moments during the 
day, i.e. milk and milk products and cheese during two bread meals (breakfast and 
lunch) and dairy desserts after dinner. In the Netherlands, current recommendations 
for the daily intake of dairy products are 450-650 mL of milk and milk products and 
20-30 g of cheese from the age of 19 y onwards56. With an average daily intake of 350-
400 mL of milk and milk products most adults do not meet this recommendation, 
whereas for cheese the recommended intake is achieved33.
In the Netherlands, milk and milk products and cheese contribute substantially to daily 
intake of calcium (69-75%), vitamin B2 (riboflavin; ~50%), vitamin B12 (cobalamin; 
~35%), phosphorus (~35%), protein (~25%), zinc (~25%), potassium (~18%), magnesium 
(~18%) and sodium (~15%)33. In the Netherlands, dairy products (except for margarine) 
are not fortified with vitamin D, but they still contribute significantly to the total 
vitamin D intake (~10%)33. Contributions to the intake of energy, fat and saturated fat 
are ~15%, ~18% and ~28% respectively33. The Dutch Nutrition Center emphasizes the 
use of (semi-)skimmed dairy products56. During the 1998 Dutch National Food 
Consumption Survey the relative contributions of full fat, semi-skimmed and skimmed 
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milk to the total consumption of milk and milk products were 18%, 53% and 29% 
respectively (Figure 1.1)33. It has been estimated that the contribution of semi-skimmed 
milk has now increased to about 85%.
Although dairy products are commonly consumed in the Netherlands, information on 
the association between dairy intake and blood pressure is scarce for the Dutch 
situation. To our best knowledge, this association has only been examined in a 
population-based cohort of 2064 Dutch men and women aged 50-75 y (Hoorn Study). 
The intake of dairy, in particular dairy desserts, milk and yogurt showed a modest 
inverse association with blood pressure18, but not with change in blood pressure22 
(Table 1.2). 
in the Netherlands, where dairy products are commonly consumed, information on the 
association between dairy intake and blood pressure is hardly available. The wide range of dairy 
intake and large variety of dairy foods that are consumed allows detailed examination of 
different dairy foods in relation to blood pressure and incidence of hypertension.
Rationale and outline of the thesis
The worldwide prevalence of hypertension is increasing rapidly, which calls for effective 
public health measures. The Dietary Approaches to Stop Hypertension (dash) trial 
showed that blood pressure reductions were more pronounced when low-fat dairy 
(among other dietary changes) was added to a fruits-and-vegetables diet. Whether 
intake of dairy products could play a role in reducing population blood pressure, 
1987-1988
1992
1997-1998
2003*
0% 20% 40% 60% 80% 100%
high-fat   semi-skimmed  skimmed
Figure 1.1 Contribution of high-fat (>3.5 g/100 g), semi-skimmed (<2 g/100 g) and skimmed 
(<0.5 g/100 g) milk products to the total consumption of milk and milk products in the Dutch 
population from 1988 to 200333, 57-59. 
*The food consumption survey of 2003 has been conducted only among young adults (19-31 y).
Time period relevant to the 
morgen study (baseline 
survey 1993-1997; Chapter 
2) and the Rotterdam Study 
(baseline survey 1990-1993 
Chapter 3)
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however, is not clear. Observational studies examining the association between dairy 
intake and blood pressure or hypertension generally suggest an inverse association, 
although data are not conclusive. Little is known about the effect of different types of 
dairy foods in relation to blood pressure. The Netherlands is a country where a wide 
variety of dairy products is consumed. This allows detailed examination of the 
association of total dairy and specific types of dairy foods with blood pressure over a 
broad range of intake. Intervention studies on dairy intake and blood pressure are 
scarce, but a fair amount of research on the blood pressure lowering potential of specific 
dairy components has been done. Calcium is considered one of the main nutrients 
responsible for a (possible) beneficial effect of dairy on blood pressure, although the 
size of effect is relatively small. Two other dairy components that have recently attracted 
much attention are lactotripeptides (ipp and vpp) and cis-9, trans-11 conjugated linoleic 
acid (cla). Promising results for ipp and vpp have been shown in Japanese and Finnish 
subjects with elevated blood pressure. The efficacy of these two lactotripeptides in 
other populations, including Dutch hypertensive subjects, has not yet been established. 
cla has recently attracted much interest because of possible favorable effects on health, 
including reduction of blood pressure in several rat models. On the other hand, cla is 
a trans fatty acids and harmful effects in the cardiovascular system cannot be excluded. 
Whether cla could influence human blood pressure is not yet clear.
The research described in this thesis was initiated to further investigate the role of 
dairy foods in relation to blood pressure and incident hypertension in the Dutch 
population (outlined in Figure 1.2). The research objectives were: 
[1]  to examine the association of dairy intake with blood pressure level and incident 
hypertension in a middle-aged (chapter 2) and older population (chapter 3), 
[2]  to focus on specific types of dairy foods in relation to hypertension in these 
populations (chapters 2 and 3), and 
[3]  to study the effect of two specific dairy components on human blood pressure, i.e. 
lactotripeptides (ipp and vpp; chapter 4) and cla (chapter 5).     
In chapter 6, the findings of the research described in this thesis are discussed, 
possible underlying mechanisms are reviewed and findings are put into public 
health perspective.
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Dairy
Types Products Components
Low-fat*
High-fat*
Fermented
Milk and 
milk products
e.g. buttermilk, yogurt, 
curds, porridge
Cheese
Desserts
Butter
 Proteins (casein, whey)
 - Peptides, e.g. ipp and vpp
 Fatty acids
 - Saturated fatty acids, 
  e.g. short chain, long chain
 - Mono and poly unsaturated fatty   
  acids e.g. trans fatty acids e.g.
Blood pressure level (Chapter 2)
Incidence of hypertension (Chapters 2 and 3)
Blood pressure change
(Chapters 4 and 5)
Intervention studiesObservational studies
cla
 Carbohydrates
 Micronutrients
 - Minerals, e.g. Ca, P, K, Mg
 - Vitamins, e.g. B2, B12, D
Figure 1.2 Schematic overview of the variety and composition of dairy. The research described in this thesis, including 
study design, is outlined in this figure by gray boxes and arrows. 
* Low-fat dairy includes milk and milk products with a fat concentration <2.0 g/100 g and cheese with a fat 
concentration <20 g/100 g, high-fat dairy includes milk and milk products with a fat concentration >3.5 g/100 g and 
cheese with a fat concentration >20 g/100 g.
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Abstract
Diet and lifestyle are important for maintaining a healthy blood pressure (bp). The role 
of dairy in the prevention of hypertension, however, is not yet clear. We studied the 
relation of dairy intake with bp in 21,553 Dutch participants aged 20-65 y who did not 
use antihypertensive medication. In addition, the risk of developing hypertension was 
examined in 3454 of these participants with 5 y follow-up. Dairy consumption was 
assessed at baseline (1993-1997) using a semiquantitative ffq that included 178 foods 
and beverages. Baseline bp and odds ratios (or) (95% ci) for incident hypertension were 
calculated in categories of energy-adjusted dairy intake with adjustment for age, sex, 
socioeconomic status, bmi, smoking, alcohol use and dietary intakes. 
Participants had a median intake of 344 g/d (~2.3 servings) for total dairy and 174 g/d 
(~1.2 servings) for low-fat dairy. Mean bp was 120/76 mm Hg. Intake of total dairy, 
specific dairy groups (i.e., low-fat, high-fat, fermented) and dairy products (i.e., cheese, 
yogurt) were not consistently related to bp. Of 3454 participants who were followed, 713 
developed hypertension. The risk of hypertension tended to be inversely related to low-
fat dairy intake, with multivariate or (95% ci) of 1.00, 0.78 (0.61, 1.00), 0.81 (0.63, 1.03) 
and 0.82 (0.64, 1.06; P-trend: 0.24) in consecutive quartiles. We conclude that variations 
in bp in a general middle-aged Dutch population cannot be explained by overall dairy 
intake. A beneficial effect of low-fat dairy on risk of hypertension, however, cannot be 
excluded, which warrants further investigation in prospective population-based 
studies.
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Introduction
Hypertension is a major public health burden. In 2025, 29% of the world population is 
expected to have hypertension1. Hypertension is associated with a doubled risk of 
cardiovascular disease and may account for 30% of all cardiovascular disease events2. 
The Dietary Approaches to Stop Hypertension (dash) trial showed that a diet emphasizing 
increased fruit, vegetables, and low-fat dairy consumption, in addition to decreased 
total and saturated fat intake, substantially lowered blood pressure (bp)3. An inverse 
association between dairy intake and bp or hypertension has been shown in a number 
of cross-sectional epidemiological studies, although findings are inconclusive4-7. In a 
prospective study among 5880 university graduates in Spain (sun cohort), low-fat dairy 
intake was associated with a remarkably lower incidence of hypertension after 2 y of 
follow-up8. Moore et al.9 observed in 95 children that diets rich in dairy products, apart 
from fruits and vegetables, had beneficial effects on bp change during childhood. Dairy 
intake, however, was not associated with bp change in the su.vi.max cohort in over 2000 
French adults4. 
The amount and type of dairy foods that are consumed in different populations varies 
considerably, which may partly explain the inconclusive findings of previous studies. In 
the Netherlands, habitual dairy intake varies widely and a large variety of dairy products 
is consumed. We investigated whether dairy consumption, including specific dairy food 
groups, was associated with bp and risk of hypertension in a Dutch population-based 
cohort of 21,553 participants aged 20-65 y. 
Methods
Study design
Data were used from the Monitoring Project on Risk Factors for Chronic Diseases 
(morgen-project), a population-based study of 23,105 men and women aged 20-65 y 
who were examined between 1993-1997 from 3 Dutch towns  (i.e. Amsterdam, 
Doetinchem and Maastricht)10. We excluded 455 participants with missing dietary or bp 
data and 1097 participants who used antihypertensive medication, leaving 21,553 men 
and women for the analysis of dairy intake and bp. 
Participants from Doetinchem (n = 6579) were invited for follow-up examination 
(including bp) in 1998-2002, and 75% (n = 4917) responded11. Participants with 
hypertension at baseline (n = 1384) or no information on hypertension during follow-
up (n = 79) were excluded, leaving 3454 participants for the analysis of dairy and 
incident hypertension. The study was approved by the Medical Ethics Committee of the 
Organization for Applied Scientific Research-Zeist, the Netherlands. 
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Dietary variables and exposure categories
Dietary intake was assessed using a validated, semiquantitative ffq that inquired about 
intake of 178 foods and beverages during the past year12. Total energy and nutrient 
intakes were calculated using a computerized Dutch Food Composition Table13. The 
reproducibility for milk and milk products after 6 and 12 mo was 0.85 and 0.73 for men 
and 0.75 and 0.78 for women, and the reproducibility for cheese was 0.77 and 0.71 for 
men and 0.67 and 0.70 for women, respectively. The validity of the ffq was assessed 
against 12 monthly 24-h recalls over a 1-y period. Spearman correlations were good for 
milk and milk products (r = 0.69 for men, r = 0.77 for women) and moderate for cheese 
(r = 0.56 and r = 0.32, respectively). 
Total dairy included all dairy foods except butter and ice cream. Milk and milk products 
included all kinds of milk, yogurt, coffee creamers, curd, pudding, porridge, custard, 
and whipping cream. Cheese included all types of cheese, as well as cheese spreads and 
cheese that was consumed during dinner or as a snack. Low-fat dairy was defined as 
milk and milk products with a fat concentration <2.0 g/100 g or cheese with a fat 
concentration <20 g/100 g. High-fat dairy was defined as milk and milk products with 
a fat concentration >3.5 g/100 g or cheese products with a fat concentration >20 g/100 g. 
Fermented dairy comprised buttermilk, yogurts, and cheese. 
Outcome measurements
bp was measured with a random-zero sphygmomanometer in sitting position by trained 
technicians. Systolic bp was recorded at the appearance of sounds (first-phase Korotkoff) 
and diastolic bp at the disappearance of sounds (5th-phase Korotkoff), followed by a 
heart rate count for 30 s. bp measurement was repeated and values were averaged. 
During physical examination, regular audits were performed to check adherence to the 
BP measuring protocol (e.g. resting time, adequate cuff size). bp data were checked for 
outliers and errors before data analysis. Hypertension was defined as systolic bp ≥140 
mm Hg or diastolic bp ≥90 mm Hg or use of antihypertensive medication. 
Collection of risk factor data
Height was measured to the nearest 0.5 cm and weight to the nearest 0.1 kg with 
participants wearing light indoor clothing without shoes. bmi was calculated as weight 
(kg) divided by height squared (m2) and overweight was defined as bmi ≥25 kg/m2. 
Participants completed a mailed questionnaire on lifestyle factors, history of major 
diseases, medication use, and any prescribed diets. Questions about physical activity 
were added in 1994 and completed by 16,642 participants (77% of the cohort). These 
questionnaire data were used to create variables on alcohol intake (6 categories), 
smoking status (current cigarette smoking, yes/no), physical activity (h/wk), and 
socioeconomic status (5 categories). 
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Statistical analysis 
Data analysis was performed using sas version 9.1 (sas Institute). Intakes of total dairy, 
dairy groups and dairy products were first adjusted for total energy intake according to 
the residual method14. Participant characteristics in quintiles of energy-adjusted total 
dairy consumption are presented as means with sd or percentages. Mean bp with 95% 
ci were obtained in energy-adjusted dairy quintiles using a general linear model, with 
adjustment for age, sex, total energy intake (continuous), bmi (continuous), current 
cigarette smoking (yes/no), socioeconomic status (5 categories), alcohol consumption 
(0, 0-1, 1-2, 2-4, 4-8, >8 glasses/d), and intake of fruit, vegetables, fish, meat, bread, coffee, 
and tea, all as continuous variables. Additional adjustment for physical activity could 
only be performed in a subgroup of 16,642 participants for whom these data were 
available. 
A number of additional predefined subgroup analyses were performed, i.e. by sex, age 
(<50 vs ≥50 y), bmi (<25 vs ≥25 kg/m2) and baseline bp (<140/90 vs ≥140/90 mm Hg). 
Most of our participants appeared to be regular dairy consumers and habitual intake in 
our cohort was relatively high. Because the impact of dairy on bp may be more 
pronounced in populations with a low habitual intake of dairy, we decided to do a post 
hoc analysis in which we further explored the association of total and low-fat dairy 
with BP at low intakes. Within the bottom quintile (4310 participants), a fully adjusted 
linear regression coefficient for bp was obtained per 50-g increase in dairy intake. The 
results of the low-dairy group were then compared with the total study population. 
Prospective analysis on incidence of hypertension was based on a smaller sample size 
(n = 3454) and energy-adjusted dairy intake was therefore divided into quartiles. Logistic 
regression models were used to obtain odds ratios (or) with 95% ci for incident 
hypertension in categories of dairy intake, with adjustment for age and sex (model 1). 
Analyses were repeated using an extended multivariate model (model 2) that included 
age, sex, total energy intake (continuous), bmi (continuous), current cigarette smoking 
(yes/no), socioeconomic status (5 categories), and alcohol consumption (0, 0-1, 1-2, 2-4, 
4-8, >8 glasses/d). Further adjustment was made for intake of fruit, vegetables, fish, 
meat, bread, coffee, and tea, all as continuous variables (model 3).
To obtain a P-value for trend across categories of dairy intake, median values of 
categories were assigned to individuals and entered continuously into the multivariate 
models. Two-sided P-values <0.05 were considered significant. 
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Results
population characteristics
Participant characteristics according to energy-adjusted dairy intake are shown (Table 
2.1). Mean bp was 120.1 ± 15.7 mm Hg systolic and 76.1 ± 10.4 mm Hg diastolic and 15% 
of the population had elevated bp (i.e. ≥140/90 mm Hg). Dairy intake was associated 
with fruit intake (positively), coffee intake (inversely), and nonsmoking. In the lowest 
dairy category, that included more men, intakes of total energy, meat, bread, and total 
and saturated fat were higher than in other categories.
Dairy consumption
The median energy-adjusted total dairy intake of the study population was 344 g/d, 
ranging from 110 g/d (i.e. <1 serving/d) in the lowest quintile to 765 g/d (i.e. >5 
servings/d) in the highest quintile. Dairy food items that contributed to total dairy 
intake are presented (Supplemental table 2.1). The Spearman correlation coefficient 
was 0.91 (P <0.0001) for the relation between total dairy and low-fat dairy and 0.41 (P 
<0.0001) for the relation between low-fat and high-fat dairy.
 
Dairy intake and Bp
bp showed little variation across quintiles of total dairy, low-fat dairy, and high-fat dairy 
(Table 2.2). For other dairy groups and products, bp was also similar across quintiles of 
intake (Supplemental table 2.2). Excluding desserts from the milk products category 
did not change the findings. Moreover, additional adjustment for complementary dairy 
food groups (e.g. low-fat dairy as a covariate when studying high-fat dairy) or saturated 
fat did not materially change the results. The results did also not change when we 
reanalyzed the data after exclusion of participants with self-reported myocardial 
infarction or diabetes and additional adjustment for prescribed diet. Furthermore, 
additional inclusion of physical activity in the model, using data of a subgroup of 
16,642 participants in whom this was assessed, did not change the results (data not 
shown). 
Subgroup analyses showed that the association between low-fat dairy and bp did not 
vary among strata of age, sex, bmi, or bp (data not shown). When we examined the 
relation between low-fat dairy and bp continuously in the total cohort, the fully adjusted 
ß (95% ci) per 50-g increase was 0.05 mm Hg (0.02, 0.09) for systolic bp and –0.04 mm 
Hg (–0.06, –0.02) for diastolic BP. In the subgroup (n = 4310) with a low habitual intake 
of dairy, these ß were 0.19 mm Hg  (–0.13, 0.50) and –0.09 mm Hg (–0.30, 0.12) per 50 g, 
respectively. 
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Dairy intake and incidence of hypertension
The subcohort that participated in the follow-up round was 49.5 ± 9.6 y and comprised 
45 % men. bp in these participants increased by 5.7 ± 12.7 mm Hg systolic and 3.1 ± 9.6 
mm Hg diastolic during a median follow-up period of 5 y and 713 (20.6%) new cases of 
hypertension were identified. 
After adjustment for potential confounders, total dairy, low-fat dairy and high-fat dairy 
were not significantly associated with risk of hypertension (P-trend 0.60, 0.24 and 0.11 
respectively) (Table 2.3). Also, other dairy groups and dairy products were not clearly 
related to risk of hypertension (Supplemental table 2.3). 
After including physical activity in the multivariate model (n = 2768), or (95% ci) in the 
consecutive quartiles of low-fat dairy were 1.00, 0.83 (0.63, 1.10), 0.81 (0.61, 1.07), and 
0.85 (0.64, 1.13) respectively (P-trend: 0.36). The association between low-fat dairy and 
hypertension risk did not vary by sex (Table 2.3) or age (data not shown). After 
stratification by bmi (<25 vs ≥25 kg/m2), or in the 2nd to the 4th quartiles of low-fat 
dairy intake were 0.95 (0.68, 1.32), 0.97 (0.70, 1.36), and 0.86 (0.61, 1.21; P-trend: 0.42) for 
participants who were overweight and 0.60 (0.42, 0.87), 0.63 (0.43, 0.91), and 0.76 (0.52, 
1.11; P-trend: 0.34), respectively for participants who were not overweight. 
Discussion
In this cohort of 21,553 Dutch adults, overall dairy intake or intake of specific dairy 
groups or dairy products was not clearly related to bp. Prospective analysis in 3454 
participants showed no consistent association of dairy intake with 5-y risk of 
hypertension, with a possible exception for low-fat dairy that was nonsignificantly 
related to a lower risk of hypertension (P-trend: 0.24). 
This study has several strengths and limitations. Our Dutch study is based in a country 
with a naturally high intake of dairy. It comprized regular consumers of a variety of 
dairy products, enabling us to examine a broad range of several types of dairy products 
in relation to bp. Total dairy intake ranged from <1 to >5 servings/d. The large sample 
size allowed more detailed examination of bp in participants who consumed a low 
amount of dairy (i.e. <185 g/d), but associations with bp were not found within this low 
range of intake. 
A major concern in epidemiological studies is residual confounding. Data on physical 
activity, an important bp determinant, was available for only 77% of our participants. 
Repeating multivariate analysis with additional adjustment for physical activity in this 
subgroup did not influence the bp associations and we think it is unlikely that 
incomplete physical activity data has impacted our findings. Dairy intake was assessed 
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by self-report, which may have led to misclassification. Assessment of dairy intake in 
our study was validated against 12 monthly repeated 24-h recalls. Milk and milk 
products were highly correlated (r = 0.7-0.8), indicating that participants could 
adequately be ranked according to milk intake12. The validity for cheese, however, was 
much lower (r = 0.4-0.5), which may have diluted the cheese-bp associations. It cannot, 
however, explain our overall null result, because cheese contributed only 8.6% to total 
dairy intake. 
Table 2.3  Association of dairy intake with incident hypertension in 3454 Dutch adults1  
  Quartiles of energy-adjusted dairy intake
 1  2  3  4  P-trend
 
n
Total dairy
 Median intake, g/d
 Incident cases, n
 or, model 12
 or, model 23
 or, model 34 
  Men (n = 1549) 
  Women (n = 1905)
Low-fat dairy
 Median intake, g/d
 Incident cases, n
 or, model 1
 or, model 2
 or, model 3
  Men (n = 1549)
  Women (n = 1905)
High-fat dairy
 Median intake, g/d
 Incident cases, n
 or, model 1
 or, model 2
 or, model 3 
  Men (n = 1549)
  Women (n = 1905)
863
206
185
1.00
1.00
1.00
1.00
1.00
59
207
1.00
1.00
1.00
1.00
1.00
43
178
1.00
1.00
1.00
1.00
1.00
863
757
177
0.98 (0.77, 1.24)
1.07 (0.83, 1.37)
1.11 (0.85, 1.44)
1.12 (0.78, 1.62)
1.12 (0.76, 1.66)
500
168
0.80 (0.63, 1.01)
0.81 (0.64, 1.04)
0.82 (0.64, 1.06)
0.86 (0.60, 1.23)
0.82 (0.57, 1.18)
166
187
1.05 (0.83, 1.34)
1.13 (0.88, 1.45)
1.19 (0.92, 1.54)
1.45 (1.03, 2.06)
1.05 (1.03, 1.06)
0.66
0.77
0.60
0.81
0.70
0.13
0.20
0.24
0.43
0.43
0.58
0.20
0.11
0.03
0.74
864
510
162
0.85 (0.67, 1.08)
0.93 (0.72, 1.20)
0.95 (0.73, 1.22)
0.78 (0.54, 1.12)
1.11 (0.76, 1.62)
296
171
0.79 (0.62, 0.99)
0.80 (0.63, 1.02)
0.81 (0.63, 1.03)
0.73 (0.52, 1.05)
0.88 (0.61, 1.25)
106
172
0.92 (0.72, 1.17)
0.91 (0.70, 1.17)
0.93 (0.72, 1.21)
0.96 (0.67, 1.39)
0.79 (0.54, 1.18)
864
359
189
1.01 (0.80, 1.27)
1.06 (0.83, 1.35)
1.08 (0.84, 1.38)
1.01 (0.73, 1.41)
1.15 (0.78, 1.69)
167
167
0.77 (0.61, 0.98)
0.78 (0.61, 0.99)
0.78 (0.61, 1.00)
0.75 (0.54, 1.04)
0.81 (0.56, 1.18)
77
176
0.94 (0.74, 1.20)
0.91 (0.70, 1.17)
0.93 (0.72, 1.19)
0.90 (0.64, 1.26)
0.87 (0.59, 1.28)
1 Values are or with 95% ci.
2 Adjusted for age and sex.
3  Adjusted for age, sex, total energy intake (mj/day), socioeconomic status (5 categories), bmi (kg/m2), smoking (yes/no), 
and alcohol intake (6 categories).  
4  Adjusted for age, sex, total energy intake (mj/day), socioeconomic status (5 categories), bmi (kg/m2), smoking (yes/no), 
and alcohol intake (6 categories) and daily intake of fruit (g), vegetables (g), fish (g), meat (g), bread (g), coffee (mL),  
and tea (mL).
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Scientific evidence for an effect of dairy on bp or hypertension is inconsistent.  Our 
data are in line with findings from the French su.vi.max study among 4652 participants 
aged 35-63 y, in which overall dairy was not associated with bp or change4. Ruidavets et 
al.6, however, reported that dairy products (range, 93 – 335 g/d) and dietary calcium 
were significantly and independently associated with lower systolic bp (7 mm Hg for 
total dairy and 4 mm Hg for calcium) in 912 French men aged 45-64 y. Also, Djoussé et 
al.5 found that dairy intake (range, 0.4–3.1 servings/d) was associated with a 38% lower 
prevalence of hypertension, independent of calcium, in the nhlbi Family Heart Study. 
Dairy intake in our study was higher (344 g/d, ~2.5 servings), which may explain 
differences in results. It may be possible that the impact of dairy intake on bp is more 
pronounced in persons with a low habitual intake of dairy. However, repeating our 
analyses within the low end of the distribution of dairy intake (0-185 g/d) yielded 
similar conclusions. In a previous cross-sectional study of 2064 Dutch men and women 
aged 50-75 y7, intake of dairy, in particular dairy desserts, milk, and yogurt, was inversely 
associated with bp. Apart from the somewhat higher dairy intake (4 servings/d), 
participants in that study were older than in our cohort, which may partly account for 
the discrepancy in findings. When reanalyzing our data in participants aged ≥50 y, 
however, we still did not find an association of dairy with bp. Snijder et al.7 found an 
association of high-fat rather than low-fat dairy with bp, in contrast to our findings for 
incident hypertension. Alonso et al.8, on the other hand, showed that low-fat dairy 
(mean intake of 140 g/d), but not high-fat dairy, was associated with a remarkable 54% 
reduced risk of hypertension during 2 y of follow-up of 5880 Spanish university 
graduates. A potential beneficial effect of low-fat dairy is consistent with the dash trial 
in which bp reductions were more pronounced when low-fat dairy (among other dietary 
changes) was added to a fruits-and-vegetables diet3. In the Coronary Artery Risk 
Development in Young Adults (cardia) study, both reduced-fat and high-fat dairy 
products were associated with a 21% reduced odds of 10-y incidence of elevated bp in 
923 young overweight adults, but not in 2234 normal weight participants15. Overall 
dairy intake was not related to 15-y incidence of elevated bp in the cardia study, 
whereas milk and dairy desserts had an inverse association16. 
It is yet unclear which specific dairy foods or components could be responsible for a 
beneficial effect on bp. Dairy is an important source of protein and minerals (e.g. 
calcium, potassium, magnesium) which may lower bp17-21. Because vitamin D is critical 
for calcium absorption and homeostasis22, vitamin D may also play a role in the 
prevention of hypertension23. Wang et al.24 showed that intakes of low-fat dairy products, 
calcium, and vitamin D were each inversely associated with risk of hypertension in 
28,886 middle-aged and older women. In the Netherlands, however, milk products have 
not yet been fortified with vitamin D. It can be speculated that low-fat dairy may be 
more beneficial to bp than high-fat dairy because of its reduced concentration of 
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saturated and natural trans fatty acids, which may mitigate the beneficial effects of 
other dairy components. 
Our findings suggest that dairy intake has little effect on population bp in a generally 
healthy population of young and middle-aged Dutch adults. We found some evidence 
for a beneficial effect of low-fat dairy on risk of hypertension, although not significant, 
which needs to be confirmed in other population-based cohort studies. 
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Supplemental table 2.1  
Dairy food items consumed by 21,553 Dutch adults
 Median intake Contribution to  
 (iqr), g/d1 total dairy intake, %
Total dairy
Milk & milk products
  Raw milk2
  High-fat milk2
  Semi-skimmed milk3 
  Skimmed milk3
  Buttermilk3, 4
  Chocolate milk3
  Milk in coffee
  High-fat yogurt2, 4 
  Semi-skimmed yogurt4
  Low-fat yogurt3, 4
 Yogurt-based drinks3, 4
 Coffee creamers2
 Curd3,4
 Pudding
 Porridge, custard
 Whipping cream2
Cheese4
 High-fat2
 Reduced fat3
344 (191,558)
308 (156,523)
11 (2,25)
14 (3,32)
40 (5,139)
12 (2,27)
0 (0,20)
15 (2,33)
2 (0,6)
0 (0,1)
7 (2,22)
8 (3,25)
0 (0,7)
6 (0,21)
5 (2,11)
6 (2,13)
8 (2,23)
2 (1,3)
29 (15,46)
24 (12,41)
2 (1,4)
91.4
4.2
8.8
24.8
5.9
11.6
7.2
1.7
0.9
3.8
5.0
5.4
3.2
2.1
2.4
3.8
0.6
8.6
7.6
1.0
1 Data presented as median values   
 (Inter Quartile Range) because of   
 skewed distribution.
2 High-fat dairy products. 
3 Low-fat dairy products.
4 Fermented dairy products.
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Abstract
Background: Little is known about the effect of different types of dairy food products 
on the development of hypertension. 
Methods: We examined the relation between dairy intake and incident hypertension in 
2245 participants of the Rotterdam Study aged 55 y and over with complete dietary and 
blood pressure data, who were free of hypertension at baseline (1990-1993). Blood 
pressure was reexamined in 1993-1995 and in 1997-1999. Hazard ratios (hr, with 
95%-confidence interval) for 2-y and 6-y incidence of hypertension were obtained in 
quartiles of energy-adjusted dairy intake, with adjustment for age, sex, bmi, smoking, 
educational level, and intake of alcohol, total energy and dietary factors.
Results: Risk of hypertension after 2 y of follow-up (664 incident cases) was inversely 
associated with dairy intake. After adjustment for confounders, hr (95% ci) were 1.00, 
0.82 (0.67, 1.02), 0.67 (0.54, 0.84), and 0.76 (0.61, 0.95) in consecutive quartiles of total 
dairy (P-trend: 0.008). Corresponding hr for low-fat dairy were 1.00, 0.75 (0.60, 0.92), 
0.77 (0.63, 0.96) and 0.69 (0.56, 0.86, P-trend: 0.003). Analysis of specific types of dairy 
showed an inverse association with milk and milk products (P-trend: 0.07) and no 
association with high-fat dairy or cheese (p >0.6). After 6 y of follow-up (984 incident 
cases), the associations with hypertension were attenuated to risk reductions around 
20% for both total and low-fat dairy between the extreme quartiles of intake (P-trend: 
0.07 and 0.09, respectively). 
Conclusion: Intake of low-fat dairy may contribute to the prevention of hypertension at 
older age. 
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Introduction 
Diet and lifestyle play an important role in blood pressure control. The dash trial 
showed that a diet rich in fruit, vegetables and low-fat dairy products can substantially 
reduce blood pressure1. Remarkably, this diet showed a more pronounced effect than a 
diet rich in fruit and vegetables in which dairy consumption was low. This drew the 
attention to the possible role of (low-fat) dairy foods in the prevention of hypertension. 
Although the underlying mechanism remains to be established, it has been linked to 
protein2, bioactive peptides3 and minerals such as calcium, potassium or 
magnesium4-8. 
The association between dairy intake and blood pressure or hypertension has been 
examined in several cross-sectional9-11 and prospective studies12-15 with results generally 
suggesting an inverse association. The nhlbi Family Heart Study showed a 36% lower 
prevalence of hypertension in American adults with a high intake of dairy products, 
independent of calcium intake9. A cross-sectional study among 912 middle-aged French 
men showed that dairy products and dietary calcium were both significantly and 
independently associated with lower levels of systolic blood pressure (7 mm Hg for 
total dairy and 4 mm Hg for calcium)10. Beneficial effects on childhood blood pressure 
have been reported in the Framingham Children’s study, for low-fat as well as high-fat 
dairy products16. The cardia study among young adults, reported a lower incidence of 
hypertension in overweight subjects with dairy consumption in the highest quartile13. 
The sun cohort study among Spanish university graduates prospectively showed that 
low-fat dairy intake, but not whole-fat dairy, was associated with 54% lower risk of 
incident hypertension in the upper quartile12. Wang et al. reported that low-fat dairy 
products, calcium, and vitamin D were each inversely associated with risk of hypertension 
in middle-aged and older women14. 
Little is known about the effect of different types of dairy food products on the 
development of hypertension. In the Netherlands, a variety of dairy products is 
commonly consumed which allows detailed examination of the association between 
different types of dairy food products and hypertension over a broad range of intake. 
In the present study, we examined whether incidence of hypertension in older Dutch 
subjects was associated with intake of total dairy, high-fat dairy, low-fat dairy, fermented 
dairy, milk and milk products, and cheese products.
Methods
Study population
The present analysis formed part of the Rotterdam Study, a population-based cohort 
study on the occurrence and progression of chronic diseases and their risk factors in 
people aged 55 y and over17. In brief, between 1990 and mid 1993 all residents of a 
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suburb of Rotterdam in this age category were invited to participate and 7983 (78%) 
subjects responded. All participants were interviewed at home and 89% of the cohort 
was physically examined during 2 baseline visits at the research center. The cohort was 
reexamined during follow-up in 1993-1995 (79% response) and 1997-1999 (76% 
response). Written informed consent was obtained from all participants. The medical 
ethics committee of Erasmus University approved the study protocol.
Dietary assessment and exposure categories
At baseline, participants completed a checklist at home that inquired foods and drinks 
they had consumed at least twice a month during the preceding year as well as dietary 
habits, use of supplements, and prescribed diets. Next, during their visit to the research 
center, they underwent a standardized interview with a trained dietician based on the 
checklist, using a 170-item semiquantitative food frequency questionnaire. A validation 
study comparing this questionnaire with a 2-week food diary demonstrated reproducible 
and valid estimates18. These dietary data were converted to total energy intake and 
nutrient intake per day with the computerized Dutch Food Composition Table taking 
seasonal variation into account19. 
For the current study, we calculated total dairy intake by summing the intake of 
individual dairy items except butter and ice cream. Subsequently, we defined five 
categories of specific types of dairy foods which are not mutually exclusive. The category 
‘milk and milk products’ included all kind of milk, yogurt, coffee creamer, curd, pudding, 
porridge, custard, and whipped cream. The category ‘cheese’ included all kind of cheese 
products, i.e. soft cheese, hard cheese and cheese spreads. The category ‘low-fat dairy’ 
was defined as all milk and milk products with a fat content less than 2.0 g/100 g and 
all cheese products with a fat content less than 20 g/100 g. The category ‘high-fat dairy’ 
was defined as all milk and milk products with a fat content above 3.5 g/100 g and all 
cheese products with a fat content higher than 20 g/100 g. The category ‘fermented 
dairy’ included all fermented dairy products such as buttermilk, yogurts, curds, and 
cheese products (both low-fat and high-fat). The food frequency questionnaire was not 
specifically validated for dairy intake. However, dairy foods are rich in protein and 
calcium; it attributes about 25-30% to the total daily protein intake and 70% to the 
daily calcium intake in the Dutch situation20. High correlations (r = 0.6-0.7) were found 
for these two dairy nutrients16.
Outcome measurements
Blood pressure measurements were taken at the research center at baseline and during 
follow-up examinations. Blood pressure was measured at the right upper arm using a 
random-zero sphygmomanometer after the participant had been seated for at least 5 
minutes. Systolic and diastolic blood pressures were calculated as the average of two 
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consecutive measurements. Hypertension was defined as a systolic blood pressure ≥140 
mm Hg or a diastolic blood pressure ≥90 mm Hg or the use of antihypertensive 
medication which was assessed at baseline and during follow-up. At the research center, 
a physician ascertained the indication for which the medication had been prescribed. 
Collection of risk factor data
Information on current health status, medical history, medication, smoking behavior 
and education was obtained by a trained research assistant who used a computerized 
questionnaire. Participants were classified as current smokers, former smokers or never 
smokers. Education was defined as low (primary education), intermediate (secondary 
general or vocational education) and high (higher vocational education or university). 
Weight and height were measured during the visit to the research center and body 
mass index (bmi) was calculated as weight in kg divided by the square of height in 
meters (kg/m2). Alcohol intake was assessed in grams of ethanol per day. Information 
on prevalent cardiovascular disease, defined as a history of myocardial infarction or 
stroke, was assessed during a home interview and verified in medical records of the 
general practitioner. Serum total cholesterol was measured with an automated 
enzymatic method in a non-fasting blood sample. Diabetes was defined as the use of 
antidiabetic medication or a post- or preload serum glucose level ≥11.1 mmol/L.
population for analysis
Our study population consisted of 5435 participants in the Rotterdam Study for whom 
a completed food frequency questionnaire was available. We excluded 2912 subjects 
with hypertension at baseline and 22 subjects without information on hypertension 
status at baseline (blood pressure not measured). Additionally, we excluded 256 without 
information on hypertension status at both follow-up examinations since they were 
either lost to follow-up (n = 128) or died (n = 128) and blood pressure was not remeasured 
after baseline. This resulted in 2245 subjects for the present analysis. Subjects who were 
excluded from the analysis did not differ with respect to blood pressure and dairy 
intake at baseline. 
Data analysis
Total dairy and intake of specific dairy food groups were adjusted for total energy 
intake according to the residual method21 and subsequently categorized into quartiles. 
We compared subject characteristics at baseline across quartiles of total energy-adjusted 
dairy intake to identify potential confounders. We used Cox proportional hazard 
modeling to estimate hazard ratios (hr with 95%-confidence interval) for incident 
hypertension in quartiles of energy-adjusted dairy intake, using the lowest quartile as 
the reference. For non-hypertensive participants, we computed person-time of follow-
up from baseline to the end of the study period. For participants who developed 
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hypertension, we attributed 1 y of follow-up if hypertension was identified during the 
2-y examination visit and 4 y of follow-up if hypertension was identified during the 6-y 
examination visit. We first calculated hazard ratios for the association between dairy 
intake and 2-y incidence of hypertension. The basic model included age (continuous) 
and sex. Subsequently, we performed a multivariate analysis (model 1) with adjustment 
for age, sex, total energy (continuous), bmi (continuous), smoking status (yes/no), 
alcohol consumption (3 categories) and educational level (3 categories). Further 
adjustment (model 2) was then made for intake of fruit (including fruit juices), 
vegetables, meat, bread, coffee, and tea (continuous). We assessed linear trends across 
dairy intake categories by entering the median values within quartiles into the model 
as a linear covariate. We performed several pre-defined stratified analyses based on 
results of previous studies examining the association between dairy intake and 
hypertension13, 22. These subgroup analyses were performed in strata of sex and 
overweight (i.e., bmi ≥25 kg/m2), using model 2. Finally, we repeated all analyses for the 
association between dairy intake and 6-y incidence of hypertension. Data-analysis was 
performed using sas software (sas Institute) version 9.1 and reported p-values are two-
sided. 
Results
Baseline characteristics
Baseline characteristics of the study population in quartiles of energy-adjusted total 
dairy intake are shown in Table 3.1. A higher dairy intake was associated with a lower 
consumption of meat, bread, and coffee. In the lowest category of dairy intake, that 
included more men and current smokers, intakes of total energy, total and saturated 
fat, and alcohol were higher than in other categories. 
Dairy consumption
The median energy-adjusted total dairy intake of the study population was 396 g/d, 
ranging from 164 g/d (i.e. ~1 serving/d) in the lowest quartile to 691 g/d (i.e. ~4.5 
servings/d) in the highest quartile. Low-fat milk (31%), buttermilk (17%), high-fat milk 
(10%), low-fat yogurt (9%) and Gouda cheese (7%) made the largest contribution to the 
total dairy intake. Total dairy was highly correlated with low-fat dairy (Spearman 
correlation, r = 0.77, p <0.0001).
Dairy intake and 2-year incidence of hypertension
During 2 y of follow-up, we identified 664 incident cases of hypertension. After adjusting 
for age, sex, bmi, educational level, smoking, total energy intake, alcohol consumption 
and several dietary factors, hazard ratios (95% ci) across increasing quartiles of total 
dairy were 1.00, 0.82 (0.67, 1.02), 0.67 (0.54, 0.84), and 0.76 (0.61, –0.95, P-trend 0.008, 
Table 3.2). Each serving/d (defined as 150 mL) increase in total dairy intake was 
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Table 3.1  Baseline characteristics of 2245 Dutch adults (≥55y) across quartiles of 
energy-adjusted total dairy intake  
 Quartiles of energy-adjusted total dairy intake
 1  2  3  4 
 
n
Median dairy intake1, g/d
Age, y
Gender, % male
Body mass index, kg/m2
Overweight (≥25 kg/m2), %
Educational level, % high
Current smoker, %
Alcohol, % abstainers
 Intake among users, g/d2
Systolic bp, mm Hg
Diastolic bp, mm Hg
History of self-reported dm, %
History of cvd, %
Total cholesterol, mmol/L
hdl cholesterol, mmol/L
Dietary intakes
 Total dairy1, g/d 
 Low-fat dairy3, g/d
 High-fat dairy4, g/d
 Fermented dairy5, g/d
 Milk & milk products6, g/d
 Cheese7, g/d 
 Meat, g/d 
 Fish, g/d 
 Bread, g/d 
 Vegetables, g/d
 Fruit, g/d 
 Coffee, mL/d
 Tea, mL/d 
 Total energy, mj/d
 Total fat, g/d
 Saturated fat, g/d 
 Total protein, g/d
 Total calcium, mg/d
561
691
65.2 ± 7.5
35
25.7 ± 3.4
56
11
24
21
4.7 (0.8, 13.2)
121.3 ± 12.3
67.9 ± 9.0
6.6
8.7
6.6 ± 1.1
1.37 ± 0.35
777 ± 251
555 ± 289
222 ± 258
295 ± 239
737 ± 253
39 ± 27
102 ± 47
15.4 ± 18.1
133 ± 54
346 ± 121
243 ± 132
492 ± 247
356 ± 253
8.6 ± 2.2
82.0 ± 27.7
33.2 ± 13.1
92.7 ± 20.5
1569 ± 399
562
472
65.7 ± 7.1
37
25.9 ± 3.4
56
13
24
17
6.2 (1.5, 14.8)
122.6 ± 11.7
68.8 ± 8.2
6.3
10.0
6.6 ± 1.2
1.37 ± 0.35
471 ± 83
315 ± 135
156 ± 144
206 ± 134
435 ± 79
36 ± 21
102 ± 45
15.1 ± 16.8
136 ± 56
344 ± 127
238 ± 121
504 ± 231
366 ± 259
8.2 ± 2.0
79.0 ± 26.1
31.2 ± 11.2
81.2 ± 18.0
1170 ± 240
561
325
65.3 ± 6.5
43
25.8 ± 3.4
58
11
23
17
6.9 (1.6, 20.0)
121.7 ± 11.9
68.6 ± 8.7
4.8
10.2
6.6 ± 1.1
1.36 ± 0.36
327 ± 82
197 ± 105
130 ± 102
148 ± 97
291 ± 79
36 ± 23
111 ± 45
16.2 ± 18.8
139 ± 54
359 ± 117
232 ± 131
509 ± 236
359 ± 247
8.3 ± 2.0
81.4 ± 25.4
31.6 ± 10.5
79.1 ± 17.4
1001 ± 242
Data are presented as mean ± sd or %. 
bmi, Body Mass Index; bp, Blood pressure; cvd, Cardiovascular diseases; dm, Diabetes Mellitus.
1 Included all dairy products except butter and ice cream.
2 Presented as median with interquartile range because of skewed distribution.
3 Defined as milk and milk products with a fat content <2.0 g/100 g or cheese products with a fat content <20 g/100 g. 
4 Defined as milk and milk products with a fat content >3.5 g/100 g or cheese products with a fat content >20 g/100 g. 
5 Included all fermented dairy products such as buttermilk, yogurts, curds, and cheese products.
6 Included all kind of milk, yogurt, coffee creamer, curd, pudding, porridge, custard and whipped cream (both low-fat and high-fat).
7 Included soft cheese, hard cheese, and cheese spreads (both low-fat and high-fat).
561
164
64.9 ± 6.7
56
25.3 ± 3.2
48
12
31
16
13.0 (3.4, 27.3)
121.8 ± 11.8
68.7 ± 8.3
4.6
11.9
6.6 ± 1.3
1.36 ± 0.36
170 ± 90
77 ± 79
93 ± 65
78 ± 62
134 ± 87
36 ± 24
126 ± 54
14.5 ± 18.2
149 ± 61
378 ± 152
211 ± 147
538 ± 277
361 ± 277
8.9 ± 2.3
90.0 ± 31.5
34.7 ± 13.1
78.1 ± 18.7
809 ± 256
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associated with a 7% lower risk for hypertension (Multivariate hr, 0.93; 95% ci, 0.89, 
0.98). When we examined the association with dairy products stratified by low or high 
fat-content, the significant inverse association was primarily limited to low-fat dairy 
intake (Table 3.2). Also, intake of milk and milk products was inversely related to 
hypertension (P-trend: 0.009), whereas intake of fermented dairy products tended to be 
inversely associated to hypertension (P-trend: 0.08). We observed no association for 
cheese products (Table 3.2). 
Table 3.2  Hazard ratios (95% ci) for 2-y incidence of hypertension by energy-adjusted dairy 
intake in 2245 Dutch adults aged 55y and over. 
  Quartiles of energy-adjusted dairy intake
 1  2  3  4  P-trend7
 
n
Total dairy1 
 Median intake, g/d
 Cases
 Age and sex adjusted 
 Model 1
 Model 2
Low-fat dairy2
 Median intake, g/d
 Model 2
High-fat dairy3
 Median intake, g/d
 Model 2
Fermented dairy4
 Median intake, g/d
 Model 2
Milk & milk products5 
 Median intake, g/d
 Model 2
Cheese & cheese products6 
 Median intake, g/d
 Model 2
561
164
190
1.00
1.00
1.00
21
1.00
28
1.00
31
1.00
127
1.00
15
1.00
561
691
156
0.76 (0.62, 0.94)
0.74 (0.59, 0.91)
0.76 (0.61, 0.95)
561
0.69 (0.56, 0.86)
272
1.02 (0.80, 1.29)
357
0.85 (0.68, 1.06)
651
0.79 (0.63, 0.99)
58
0.95 (0.75, 1.21)
0.006
0.003
0.008
0.003
0.77
0.08
0.009
0.60
562
472
150
0.70 (0.56, 0.86)
0.66 (0.53, 0.83)
0.67 (0.54, 0.84)
325
0.77 (0.63, 0.96)
131
1.20 (0.95, 1.51)
188
0.80 (0.64, 1.00)
434
0.66 (0.53, 0.83)
39
1.18 (0.95, 1.46)
561
325
168
0.86 (0.70, 1.06)
0.82 (0.67, 1.02)
0.82 (0.67, 1.02)
175
0.75 (0.60, 0.92)
80
0.96 (0.76, 1.21)
97
0.97 (0.79, 1.20)
288
0.92 (0.75, 1.14)
28
1.18 (0.95, 1.47)
1 Included all dairy products except butter and ice cream.
2 Defined as milk and milk products with a fat content <2.0 g/100 g or cheese products with a fat content <20 g/100 g. 
3 Defined as milk and milk products with a fat content >3.5 g/100 g or cheese products with a fat content >20 g/100 g. 
4 Included all fermented dairy products such as buttermilk, yogurts, curds, and cheese products.
5 Included all kind of milk, yogurt, coffee creamer, curd, pudding, porridge, custard and whipped cream (both low-fat and high-fat).
6 Included soft cheese, hard cheese, and cheese spreads (both low-fat and high-fat).
7 Linear trend across quartiles was tested by entering the median values within quartiles into the model as covariate.
Model 1: Adjusted for age (continuous), sex, bmi (continuous), smoking (yes/no), educational level (3 categories), total energy 
intake (continuous), and alcohol consumption (3 categories)
Model 2: as model 1 with additional adjustment for intake of vegetables, fruit (including fruit juices), meat, bread, coffee, and tea 
(all continuous)
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The association between dairy intake and hypertension did not significantly vary by 
sex. Hazard ratios for low-fat dairy in the upper vs lower quartiles of intake were 0.61 
(0.43, 0.88) for men and 0.74 (0.55, 0.98) for women (P-trend: 0.03 and 0.04, respectively). 
When we stratified our analyses by bmi (bmi <25 vs ≥25 kg/m2), hazard ratios across 
increasing categories of low-fat dairy intake were 1.00, 0.82 (0.58, 1.15), 0.83 (0.58, 1.18), 
0.98 (0.69, 1.38) in lean subjects (P-trend: 0.92) and 1.00, 0.69 (0.63, 0.91), 0.71 (0.54, 
0.94), 0.55 (0.41, 0.73) in overweight subjects (P-trend: <0.001). 
Dairy intake and 6-year incidence of hypertension
After 6 y of follow-up, 984 subjects suffered from hypertension. The associations with 
hypertension were attenuated with hazard ratios of 0.81 (0.70, 1.01) both for total and 
low-fat dairy in the upper vs lower quartiles of intake (P-trend: 0.07 and 0.09, respectively), 
whereas fermented dairy intake was no longer related to hypertension risk (P-trend: 
0.92, Table 3.3). 
When we stratified our analyses by sex, hazard ratios across increasing categories of 
low-fat dairy intake were 1.00, 0.82 (0.64, 1.07), 0.79 (0.60, 1.05), 0.75 (0.56, 0.99) in men 
(P-trend: 0.04) and 1.00, 0.90 (0.69, 1.17), 0.82 (0.64, 1.06), 0.90 (0.70, 1.16) in women 
(P-trend: 0.45). The association between low-fat dairy intake and 6 y incidence of 
hypertension stratified by bmi did only vary in the highest categories of dairy intake: 
hazard ratios across increasing categories of low-fat dairy intake were 1.00, 0.80 (0.60, 
1.05), 0.72 (0.54, 0.97), 1.01 (0.77, 1.33) in lean subjects (P-trend: 0.99) and 1.00, 0.90 
(0.71, 1.15), 0.84 (0.66, 1.08), 0.76 (0.59, 0.97) in overweight subjects (P-trend: 0.03). 
Discussion
In this prospective cohort study among 2245 older Dutch adults, we found an inverse 
association of total dairy and low-fat dairy intake with risk of developing hypertension. 
Larger risk reductions were observed after 2 y than 6 y of follow-up and among subjects 
with overweight. Consumption of milk and milk products was inversely associated with 
incident hypertension, whereas high-fat dairy and cheese were not related to risk of 
hypertension. Although fermented dairy tended to be inversely associated with incident 
hypertension after 2 y, this association was no longer present after 6 y.
Several strengths and limitations of our study need to be addressed. In the Netherlands, 
a variety of dairy products is commonly consumed (median intake around 400 g/d in 
this study), which enabled us to examine the association of different dairy foods with 
hypertension over a broad range of intake. A possible limitation is misclassification of 
dairy intake, which was based on self-report. Assessment of dietary intake in our study 
was validated against multiple food records. Although the food frequency questionnaire 
was not specifically validated for dairy intake, high correlations were found for protein 
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Table 3.3  Hazard ratios (95% ci) for 6-y incidence of hypertension by energy-adjusted dairy 
intake in 2245 Dutch adults aged 55y and over.
  Quartiles of energy-adjusted dairy intake
 1  2  3  4  P-trend7
 
n
Total dairy1
 Median intake, g/d
 Cases
 Age and sex adjusted 
 Model 1
 Model 2
Low-fat dairy2
 Median intake, g/d
 Model 2
High-fat dairy3
 Median intake, g/d
 Model 2
Fermented dairy4
 Median intake, g/d
 Model 2
Milk & milk products5
 Median intake, g/d
 Model 2
Cheese & cheese products6
 Median intake, g/d
 Model 2
561
164
260
1.00
1.00
1.00
21
1.00
28
1.00
31
1.00
127
1.00
15
1.00
561
691
244
0.85 (0.71, 1.02)
0.82 (0.69, 0.99)
0.84 (0.70, 1.01)
561
0.84 (0.70, 1.01)
272
0.93 (0.76, 1.13)
357
0.96 (0.80, 1.16)
651
0.83 (0.69, 1.01)
58
0.98 (0.81, 1.18)
0.08
0.05
0.09
0.07
0.66
0.92
0.07
0.76
562
472
239
0.80 (0.67, 0.96)
0.77 (0.64, 0.93)
0.78 (0.64, 0.93)
325
0.81 (0.67, 0.97)
131
0.94 (0.77, 1.14)
188
0.90 (0.74, 1.08)
434
0.75 (0.63, 0.91)
39
0.96 (0.80, 1.16)
561
325
241
0.85 (0.71, 1.02)
0.83 (0.69, 0.99)
0.82 (0.68, 0.98)
175
0.86 (0.72, 1.04)
80
0.90 (0.75, 1.09)
97
0.91 (0.76, 1.09)
288
0.81 (0.67, 0.97)
28
0.99 (0.82, 1.19)
1 Included all dairy products except butter and ice cream.
2 Defined as milk and milk products with a fat content <2.0 g/100 g or cheese products with a fat content <20 g/100 g. 
3 Defined as milk and milk products with a fat content >3.5 g/100 g or cheese products with a fat content >20 g/100 g. 
4 Included all fermented dairy products such as buttermilk, yogurts, curds, and cheese products.
5 Included all kind of milk, yogurt, coffee creamer, curd, pudding, porridge, custard and whipped cream (both low-fat and high-fat).
6 Included soft cheese, hard cheese, and cheese spreads (both low-fat and high-fat).
7 Linear trend across quartiles was tested by entering the median values within quartiles into the model as covariate.
Model 1: Adjusted for age (continuous), sex, bmi (continuous), smoking (yes/no), educational level (3 categories), total energy 
intake (continuous), and alcohol consumption (3 categories)
Model 2: as model 1 with additional adjustment for intake of vegetables, fruit (including fruit juices), meat, bread, coffee, and tea 
(all continuous)
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and calcium (r = 0.6-0.7)18. Moreover, the Netherlands is a country where dairy products 
form part of a traditional diet. About 75% of the dairy products is consumed at typical 
moments during the day, i.e. milk and milk products and cheese during two bread 
meals (breakfast and often lunch) and dairy desserts after a warm meal (often dinner)20. 
We, therefore, assume that subjects were able to recall their dairy intake in such way 
that they could be adequately ranked. Errors in the measurement of dairy intake are 
likely to bias toward the null hypothesis (no association between dairy intake and 
hypertension), resulting in an underestimation of the true magnitude of the association. 
We observed somewhat weaker associations when examining baseline dairy intake in 
relation to 6-y risk compared to 2-y risk of hypertension which we cannot fully explain. 
Dairy intake may better predict short-term (2 y) than long-term (6 y) onset of 
hypertension. This raises the hypothesis that dairy may slow the progression rather 
than prevent the development of hypertension in certain individuals. Alternatively, 
participants could have changed their diet between 2 and 6 y of follow-up resulting in 
attenuation due to misclassification of exposure. Finally, it could be possible that 
individuals who are (most) susceptible for a beneficial effect of dairy may already 
benefit in 2 years, while individuals who do not ‘respond’ within 2 years will also not 
‘respond’ in 6 years. For example, development of hypertension may be secondary to 
the development of another disease which is not responsive to dietary intake. 
The extensive data collection of the Rotterdam Study allows control for many potential 
confounders. We had no data on physical activity which is a known determinant of 
blood pressure. Although we did adjust for total energy and body mass index as 
surrogate markers for physical activity, we cannot exclude residual confounding. A 
questionnaire on physical activity has been added to the Rotterdam Study in 1997 
(second follow-up round) and data has recently become available for a subpopulation 
(n~600 for the present study). Dairy intake was not clearly related to physical activity 
expressed as met-h/w in this subpopulation; 102 ± 52 h/w (n = 207), 109 ± 55 h/w (n = 
208), 108 ± 50 h/w (n = 221), and 103 ± 48 h/w (208) for the consecutive categories of 
total dairy intake (P-trend: 0.40). 
Several observational studies have shown an inverse association between dairy intake 
and blood pressure or hypertension9-16. These studies have been conducted in children16, 
young adults13, 15, middle-aged10, 12, 14 or older adults14. Our study in a general older 
population largely agrees with previous reports, including the study by Wang et al. who 
found that total and low-fat dairy were associated with reduced risk of hypertension of 
about 10-15% in middle-aged and older women14. We observed that risk reductions were 
more pronounced among individuals with overweight compared to lean individuals. 
This is in line with the study by Pereira et al. who observed significant associations only 
among overweight individuals13. In contrast with previous studies, we observed no clear 
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‘dose-response relation’ between dairy intake and hypertension, but rather a ‘threshold 
effect’. While especially a low dairy intake was associated with an increased risk of 
hypertension, risk estimates across higher dairy intakes were more or less similar. 
Dairy intake is a rather heterogeneous exposure and little is known about specific types 
of dairy foods in relation to blood pressure. Although both total and low-fat dairy were 
inversely related to hypertension risk, the effect of total dairy is probably due to its high 
correlation with low-fat dairy (r = 0.77, p<0.0001). Most of the dairy products in the dash 
diet were in the form of low-fat milk (74%) and fat-free yogurt (18%)23. Observational 
studies that examined the association with dairy products stratified by fat content 
mainly observed beneficial effects of low-fat dairy rather than high-fat dairy12, 14, although 
results are not conclusive11, 16. It is not clear why especially low-fat dairy products could 
affect blood pressure, but it is speculated that saturated fats may mitigate the beneficial 
effects of other dairy components. This would also explain the weaker or null association 
with high-fat dairy food groups (i.e. high-fat dairy, fermented dairy and cheese) in our 
study. Another concern with respect to dairy intake is related to (high) sodium levels in 
all ‘salted’ cheese products which is a well-established risk factor for hypertension24, 25. 
Because our cheese category consisted mainly of regular high-fat (hard/salted) cheese 
products, this probably explains why we did not observe an association for this category. 
Other studies that examined the relation between cheese and blood pressure observed 
no association either inverse or direct11, 13, 15, except for Ruidavets et al. who showed that 
fresh cheese was inversely related to blood pressure10.
The mechanism via which dairy may reduce blood pressure remains to be established. 
Dairy is rich in protein and bioactive peptides which might exert a beneficial effect on 
blood pressure, e.g. by inhibiting the angiotensin-i-converting enzyme, modulating 
endothelium function or by affecting body weight. Likewise, minerals in dairy foods, 
such as calcium, magnesium and potassium, are important for blood pressure regulation 
and have been associated with a reduced risk of hypertension4-8. A meta-analysis of 40 
randomized controlled trials showed that calcium supplementation may significantly 
reduce blood pressure, especially in populations with a habitually low calcium intake26. 
Moreover, studies addressing this topic have shown greater consistency using whole 
foods than using non-dietary calcium supplements6, suggesting the importance of the 
total dietary pattern. 
Blood pressure is a major risk factor for cardiovascular diseases. A population-wide shift 
in systolic blood pressure distribution of 2-5 mm Hg has been translated into important 
reductions in mortality due to stroke and coronary heart disease and in total mortality24, 
27. The results from our study suggest that low-fat dairy could play a role in the prevention 
of hypertension in a general older population.
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Abstract
Milk derived peptides with ace-inhibiting properties may have antihypertensive effects 
in humans. We conducted a randomized double-blind placebo-controlled trial to 
examine the blood pressure lowering potential of 2 ace-inhibiting lactotripeptides, i.e. 
Isoleucine-Proline-Proline and Valine-Proline-Proline. We included 135 Dutch subjects 
with elevated systolic blood pressure who were otherwise healthy and who received no 
current antihypertensive treatment. After a 2-week run-in period on placebo, subjects 
randomly received a daily dose of 200 mL dairy drink with 14 mg lactotripeptides 
obtained by concentrating fermented milk, enzymatic hydrolysis, or chemical synthesis, 
or placebo for 8 weeks, followed by a 2-week wash-out. The primary outcome was 8-week 
change in office systolic blood pressure. Secondary outcomes were change in diastolic 
blood pressure, home blood pressure, 24-hour ambulatory blood pressure, plasma ace-
activity, and plasma angiotensin ii. Blood pressure at baseline was on average 142/84 
mm Hg. Lactotripeptides did not significantly change systolic blood pressure (P = 0.46) 
or diastolic blood pressure (P = 0.31) compared with placebo. The mean difference (95% 
ci) in systolic blood pressure response between treatment and placebo was 2.8 mm Hg 
(–2.6, 8.2) for concentrated fermented milk lactotripeptides, –0.5 mm Hg (–6.0, 5.0) for 
enzymatic lactotripeptides and 1.6 mm Hg (–3.9, 6.9) for synthetic lactotripeptides. 
Treatment neither had a significant effect on secondary outcome measures. In 
conclusion, the present study does not support the hypothesis of a blood pressure 
lowering effect of the lactotripeptides Isoleucine-Proline-Proline and Valine-Proline-
Proline.
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Introduction
There is growing evidence for a beneficial effect of dairy intake on blood pressure1. In 
the Dietary Approaches to Stop Hypertension (dash) trial larger blood pressure reductions 
were achieved when low-fat dairy was added to a healthy fruit and vegetable diet2. Dairy 
food is rich in protein and calcium, which could have beneficial effects on blood 
pressure3-5. In addition, fermented milks and casein hydrolysates decreased blood 
pressure in a number of Japanese and Finnish trials in (mildly) hypertensive human 
subjects6-14. Studies of fermented milk showed reductions of 1.5 to 11.0 mm Hg for 
systolic blood pressure (sbp) and 0.5 to 6.8 mm Hg for diastolic blood pressure (dbp), 
compared with placebo6-8, 10, 12-14. The proposed underlying antihypertensive mechanism 
of these bioactive peptides is, at least partly, ace-inhibition. Isoleucine-Proline-Proline 
(ipp) and Valine-Proline-Proline (vpp), 2 lactotripeptides (ltp), are considered the most 
promising ace-inhibiting bioactive peptides. ipp and vpp can be derived from milk casein 
by the action of the proteolytic system of lactic acid bacteria (Lactobacillus helveticus). 
Recently, an enzymatic method using an Aspergillus oryzae protease has been developed 
to generate ipp and vpp from milk casein15. This casein hydrolysate decreased blood 
pressure in Japanese hypertensive subjects9, 11. Both fermented and enzymatically 
hydrolyzed milk contain a large variety of peptides. Therefore, supplementation with 
chemically synthesized ipp and vpp may be more appropriate for studying specific effects 
of these peptides. An antihypertensive effect of chemically synthesized ipp and vpp has 
been demonstrated in spontaneously hypertensive rats16, 17, but not yet in humans. 
We performed a randomized double-blind placebo-controlled trial to examine whether 
daily intake of 14 mg ltp, obtained by concentrating fermented milk, enzymatic 
hydrolysis, or chemical synthesis, would influence blood pressure over an 8-week period 
in 135 Dutch subjects with elevated blood pressure who received no current 
antihypertensive treatment. 
Subjects and Methods
Subjects
Men and women (35 to 70 y) with elevated sbp were recruited from the Dutch population 
in collaboration with general practitioners. During a screening phase 2 consecutive 
blood pressure measurements were performed at the study center with at least 48 hours 
in between. Subjects with elevated blood pressure, defined as sbp ≥140 mm Hg (mean of 
last 3 of 4 measurements, taken after 15-minute rest at 2-minute intervals) on both 
occasions, were invited for further screening. Subjects were excluded if they reported 
metabolic diseases, gastrointestinal disorders, cardiovascular disease, or renal disease. 
Plasma glucose, liver function (alat, asat, -gt), renal function (ureum and creatinine), 
and hematology (wbc, rbc, hemoglobin, hematocrit, platelet count) had to be normal 
based on the judgement of general practitioners, who evaluated these data for their own 
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patients. Additional exclusion criteria were: antihypertensive medication less than 3 
weeks before screening; body mass index >32 kg/m2; weight loss (>10%) during 6 months 
before screening; cow milk allergy or lactose intolerance; pregnancy or lactation; blood 
donation; alcohol abuse; and participation in night shift work. The Medical Ethics 
Committee of Wageningen University approved the study and all subjects gave written 
informed consent. In addition, agreement was obtained from each subject’s general 
practitioner. The study was conducted in accordance with the principles of the Declaration 
of Helsinki.
Design and randomization procedure
We performed a randomized double-blind placebo-controlled trial with 4 parallel arms. 
Baseline measurements took place at the end of a 2-week run-in period during which 
subjects consumed the placebo product (i.e., dairy drink without ltp) and followed study 
guidelines as described below. Two independent persons, not involved in the conduct of 
the study, randomly allocated eligible subjects to 1 of the 3 treatment groups or placebo 
by means of computer-generated randomization codes stratified by prestudy use of 
antihypertensive medication (yes versus no), baseline sbp (<150 mm Hg, 150 to 160 mm 
Hg, or >160 mm Hg), and gender. Subjects took one study drink each morning for an 
8-week period. An additional blood pressure measurement was performed after a 2-week 
wash-out period.
Dairy drinks
Test products were low-fat yogurt drinks that were ready-to-drink and provided by 
Unilever Food & Health Research Institute, Vlaardingen, the Netherlands. Table 4.1 
shows the nutritional composition of the products. The 3 treatment products contained 
ipp and vpp, which are lactotripeptides (ltp) generated by concentrating fermented milk, 
enzymatic hydrolysis, or chemical synthesis. Daily supply of dairy drink per subject was 
200 mL, containing 4.2 to 5.4 mg ipp and 5.0 to 5.8 mg vpp, which equals 14 mg ltp 
equivalents in all active arms. ace-inhibitory activity of the test products was analyzed 
according to Matsui et al18. The fermented and enzymatic ltp drinks had an ace-inhibition 
of 50% using a concentration of 0.025% protein of the added active powder. The synthetic 
ltp drink had an ace-inhibition of 45% using a 1000 times lower protein concentration. 
The placebo drink did not show any ace-inhibition. Additionally, all test products 
contained orange juice concentrate, sugars, flavors for taste, pectin for stability, and 
water. Test products were similar in appearance, color, taste and smell, and were provided 
in nontransparent white cups every 2 weeks. Two research assistants, not otherwise 
involved in the study, labeled and supplied the test products. Compliance was assessed 
by counting all empty and full cups that were returned by subjects. Research staff and 
subjects remained blinded towards the type of treatment during the study and data 
analysis.
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Study procedures 
Height was measured to the nearest 0.5 cm using a wall-mounted stadiometer. Body 
weight was measured without shoes and heavy clothing at each visit (Seck Bascule mt), 
and body mass index was computed (kg/m2). At baseline, subjects filled out a 21-item 
food frequency questionnaire for intake of dairy products from which daily protein 
and calcium intake were computed using Dutch food composition tables (nevo, The 
Hague, 2001). 
Subjects recorded consumption of test products, deviations from the study protocol, 
episodes of illness or hospitalization, use of medication, and health complaints in a 
diary. Adverse events were coded by the study physician (egs) according to the 
International Classification of Diseases (icd10).
Subjects were asked to maintain their habitual dietary and lifestyle pattern during the 
study. In particular they were asked not to change intake of salt and salty foods, alcoholic 
beverages, and fermented products. Subjects were instructed to consume the test 
product daily at breakfast. At the day before a test day at the study center, subjects were 
asked to fast from 8 pm onwards. They were allowed to consume breakfast and test 
product on test days, but at a fixed point in time at least 2 hours before their appointment 
at the study center. 
Blood pressure measurements
Blood pressure measurements were performed at the study center (office bp) and by 
subjects themselves at home (home bp). In 58 subjects (43%) we additionally obtained 
Table 4.1  Nutrient composition per 100 g of dairy drinks (daily dose1)
Nutrient Fermented ltp2 Enzymatic ltp Synthetic ltp Placebo 
Calorie, kcal
Protein, g
Carbohydrates, g
Fat, g
Calcium, mg
Sodium, mg
Potassium, mg
Magnesium, mg
Lactotripeptides
 IPP3, mg
 VPP4, mg
61 (122)
2.7 (5.4)
12.5 (25.0)
-
75 (150)
35 (70)
153 (306)
9 (18)
-
-
60 (120)
2.7 (5.4)
12.4 (26.8)
-
71 (142)
32 (64)
147 (294)
9 (18)
2.6 (5.2)
2.5 (5.0)
61 (122)
2.8 (5.6)
12.5 (25.0)
-
71 (142)
45 (90)
147 (294)
9 (18)
2.7 (5.4)
2.5 (5.0)
1 Subjects took 200 mL daily.
2 ltp indicates lactotripeptides (ipp and vpp). 
3 ipp, Isoleucine-Proline-Proline.
4 vpp, Valine-Proline-Proline. 
64 (128)
2.6 (5.2)
13.4 (26.8)
-
95 (190)
34 (68)
146 (292)
13 (26)
2.1 (4.2)
2.9 (5.8)
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24-hour ambulatory blood pressure readings (abpm). Subjects remained blinded toward 
all blood pressure values until data analysis was completed. The primary outcome 
measure was 8-week change in sbp measured at the study center.
Trained staff measured blood pressures at the study center during screening, at baseline, 
after 4 weeks, after 8 weeks, and after the 2-week wash-out period. After a 15-minute 
rest, 4 measurements with 2-minute intervals were performed on the dominant arm in 
sitting position, using an automated blood pressure device with an appropriately sized 
cuff (Omron hem-907). The first reading was discarded, and 3 subsequent readings were 
averaged. Blood pressure measurements were repeated after 1 day and values of both 
occasions were averaged. All blood pressure measurements were performed between 8 
and 12 am at a fixed time for each individual.
Subjects performed measurements at home on the same days as the study center visits 
according to the same standardized procedures. They measured blood pressure using a 
blinded automated device (Stabil-O-Graph) at 3 fixed time points: in the morning 
between awakening and breakfast, before lunch, and before bedtime. Readings were 
stored and downloaded afterwards on a computer at the study center. A group of 58 
subjects volunteered for 24-hour abpm at baseline, week 4 and week 8. Measurements 
were performed from 12 am till 12 am next day with 30-minutes intervals during the 
day (7 am to 11 pm) and 60-minutes intervals during the night (11 pm to 7 am), using a 
blinded automated device (Space Lab type 90217). Readings were stored and downloaded 
afterward on a computer at the study center. Mean 24-hour, day (9 am to 9 pm), and 
night (1 am to 6 am) values were calculated.
Laboratory determinations
Research nurses performed blood sampling at screening, baseline and after 4 and 8 
weeks of intervention. During screening, they used venipuncture. During the study, the 
nurses inserted a catheter into the antecubital vein, after which the subject rested for 
20 minutes before blood was taken by a syringe. The collected blood was directly 
processed on ice and stored at –80°C. For determination of ace-activity blood was 
collected in Li-heparin tubes. Plasma ace-activity was assessed in duplicate by use of a 
fluorescence assay (BiPharma, Fujirebio Diagnostics Inc), with an intraassay coefficient 
of variation of 3.8% and an interassay coefficient of variation of 5.8%. For the 
determination of Angiotensin ii blood was collected in chilled edta tubes containing 
ace and renin inhibitors to prevent conversion. Before determination, plasma was 
treated with Sep-Pak C18 columns. Subsequently, plasma concentration of Angiotensin 
ii was assessed in duplicate by Radioimmunoassay (Penninsula Laboratories Inc Europe), 
with an intraassay coefficient of 4.6% and interassay coefficient of 7.7%. All samples of 
each subject were analyzed in one run. Plasma glucose, liver enzymes, indicators of 
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renal function and hematology were assessed during screening and after 8 weeks using 
standard laboratory methods. 
At baseline and after 8 weeks, 24-hour urine collections were obtained for determination 
of sodium and potassium excretion. Creatinine was measured to check completeness of 
urine collection. Urinary volume and collection times were used to calculate 24-hour 
excretion of sodium and potassium. 
Statistical analysis
Double-data entry was performed and discrepancies were solved. Treatment codes were 
broken after blind data analysis. Data were analyzed according to the intention-to-treat 
principle. 
Values reported in text and tables are means with standard errors (se) or 95%-confidence 
intervals (95% ci), unless stated otherwise. Response to treatment was defined as change 
in blood pressure from baseline. Blood pressure data were analyzed using analysis of 
variance (anova). Subsequently, the Dunnett test was used to compare mean changes 
within different treatment groups with that of the control group. Data analysis was 
repeated after exclusion of noncompliant subjects who consumed less than 80% of the 
test products. 
To examine whether dairy calcium or protein in the background diet would modify 
blood pressure response to intake of ltp (all 3 treatment groups combined), we 
performed a post-hoc analysis in 118 subjects who completed the food frequency 
questionnaire. For this purpose, blood pressure effects were reexamined after 
stratification for dairy calcium intake (below versus above the median of 726 mg per 
day) and for dairy protein intake (below versus above the median of 24 g per day). 
Analyses were performed using spss 11.0.1 for Windows. Two-sided probability values 
below 0.05 were considered statistically significant. The present study had a power of 
83% for detecting a 5 mm Hg difference in systolic blood pressure response, with =0.05 
(2-sided).
Results
Subjects and compliance
We enrolled 135 subjects in the trial. One subject dropped out after 3 weeks for personal 
reasons not related to the study. Figure 4.1 shows the number of subjects screened, 
excluded, and randomized. There were no relevant differences in subject's characteristics, 
including blood pressure, among the groups (Table 4.2). Compliance was satisfactory, 
with only 4 subjects consuming less than 80% of the test products. 
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Blood pressure
Figure 4.2 shows mean office sbp and dbp in the 4 groups throughout the study. There 
was no significant effect of ltp treatment on sbp (P = 0.46). The mean difference (95% ci) 
in 8-week change between treatment and placebo was 2.8 mm Hg (–2.6, 8.2) for 
concentrated fermented milk based ltp, –0.5 mm Hg (–6.0, 5.0) for enzymatic ltp and 1.6 
mm Hg (–3.9, 6.9) for synthetic ltp (Table 4.3). ltp treatment did neither affect dbp (P = 
0.31, Table 4.3). Exclusion of 4 noncompliant subjects yielded similar results (data not 
shown).
Mean home blood pressure at baseline in the group as a whole was 153/95 mm Hg, i.e., 
149/94 mm Hg in the morning, 150/94 mm Hg at noon and 158/98 mm Hg in the 
evening. Values were similar for treatment and placebo groups. ltp treatment did not 
significantly affect home blood pressure (all probability values >0.3). The mean 
difference (95% ci) in home sbp response between treatment and placebo was –0.9 mm 
36 Allocated to 
Synthetic ltp
13 participated in abpm
32 Allocated to 
Enzymatic ltp
17 participated in abpm
32 Allocated to 
Placebo
14 participated in abpm
35 Allocated to 
Fermented ltp
14 participated in abpm
32 completed 
intervention
35 completed 
intervention
36 completed 
intervention
31 completed 
intervention
1 withdrew
135 Randomized
 323 Excluded
 319 did not meet entry criteria
 4 withdrew during run-in period
458 Screened
Figure 4.1 Flow chart of a double-blind, randomized, placebo-controlled trail of lactotripeptides and blood pressure in 
135 Dutch subject with untreated elevated blood pressure. 
ltp, lactotripeptides (ipp and vpp)
abpm, 24h ambulantory blood pressure measurement 
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Hg (–6.1, 4.4) for concentrated fermented milk based ltp, –1.8 mm Hg (–7.2, 3.6) for 
enzymatic ltp and 0.6 mm Hg (–4.7, 5.9) for synthetic ltp. Detailed data on home blood 
pressure responses throughout the day are tabulated in the online supplement to this 
paper (Supplemental table 4.1). Mean abpm in 58 subjects was 144/87 mm Hg at 
baseline, with higher values during the day (150/90 mm Hg) than the night (123/72 
mm Hg). Changes in 24-hour sbp during intervention in the 3 active arms were not 
significantly different from placebo (all P >0.3): the mean difference (95% ci) in 24-hour 
sbp response (12 am to 12 am) was 4.6 mm Hg (–3.1, 12.3) for concentrated fermented 
milk based ltp, 2.6 mm Hg (–4.7, 9.9) for enzymatic ltp and 4.2 mm Hg (–3.6, 12.1) for 
synthetic ltp. Results were similar for daytime and nighttime sbp, and for different 
measures of dbp. Additional ambulatory 24-hour sbp curves for each group are shown 
in the online supplement to this paper (Supplemental figures 4.1 and 4.2). Restricting 
the analysis to 46 compliant subjects (i.e., subjects with over 70% readings and more 
than 20 hours on each occasion) yielded similar results.
Table 4.2  Baseline characteristics of 135 subjects with untreated elevated blood pressure, 
by treatment 
Characteristic Fermented ltp1 Enzymatic ltp Synthetic ltp Placebo
 (n = 35) (n = 32) (n = 36) (n = 32) 
Age, y
Sex, male/female
Blood pressure category, n (%)3
 Optimal
 Normal
 High normal
 Hypertension
  Stage 1
  Stage 2-4
Resting heart rate, beats/min
Pre-study use of antihypertensive 
medication (past 3 mo), n (%)4
Body weight, kg
Body Mass Index, kg/m2
Current cigarette smoking, n (%)4
Glucose, mmol/L4
Dairy protein intake, g/d4
Dairy calcium intake, mg/d4
58.9 ± 10.3
20/12
1 (3)
5 (26)
9 (28)
14 (44)
3 (10)
67.5 ± 7.5
1 (3.1)
83.5 ± 13.5
26.8 ± 2.9
3 (9)
5.9 ±  0.1
29 ±  17
926 ± 589
59.5 ± 8.2
23/13
2 (6)
4 (11)
10 (28)
16 (44)
4 (11)
68.1 ± 8.0
3 (8.3)
83.2 ± 12.2
27.0 ± 2.9
5 (14)
6.0 ±  0.1
26 ± 13
811 ± 419
54.2 ± 8.8
22/10
1 (3)
6 (19)
7 (22)
14 (44)
4 (13)
74.9 ± 7.5
2 (6.3)
84.7 ± 11.1
26.8 ± 2.8
3 (9)
5.8 ±  0.1
25 ± 10
807 ± 334
1 ltp indicates lactotripeptides (ipp and vpp).
2 Values are mean (±sd) or percentages.
3 None of the subjects used antihypertensive medication at baseline. Blood pressure categories defined as follows: 
 Optimal, sbp <120 mm Hg and dbp <80 mm Hg; Normal, 120-129 mm Hg for sbp or 80-84 mm Hg for dbp; 
 High normal, 130-139 mm Hg for sbp or 85-89 mm Hg for dbp; Hypertension – stage 1 (mild), 140-159 mm Hg for sbp 
 or 90-99 mm Hg for dbp; Hypertension – stage 2-4, ≥160 mm Hg for sbp or ≥110 mm Hg for dbp.
4 Assessed during screening.
58.8 ± 9.12
23/12
1 (3)
4 (11)
11 (31)
17 (49)
2 (6)
68.6 ± 8.6
5 (14.3)
81.8 ± 12.3
26.9 ± 2.6
3 (9)
6.0 ±  0.1
24 ± 10
738 ± 316
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Figure 4.2  Mean values (se) for office systolic and diastolic blood pressure during run-in, intervention and 
wash-out in 135 randomized subjects in the three treatment groups and the placebo group.
sbp, systolic blood pressure
dbp, diastolic blood pressure
ltp, lactotripeptides (ipp and vpp)
Fermented LTP 
Enzymatic LTP 
Synthetic LTP 
Placebo
Fermented LTP 
Enzymatic LTP 
Synthetic LTP 
Placebo
Treatment
Treatment
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Other outcomes
Body weight did not change significantly during the study. Mean changes (±sd) were: 
0.4 ± 0.2 kg for concentrated fermented milk based ltp, 0.0 ± 0.2 kg for enzymatic ltp, 
0.1 ± 0.2 kg for synthetic ltp, and 0.0 ± 0.2 kg for placebo. In the group as a whole, 
baseline urinary 24-hour excretion of sodium, potassium, and creatinine (±sd) were 
168.2 ± 5.9 mmol (corresponding to 9.7 g NaCl per day), 91.1 ± 2.6 mmol (3.5 g), and 13.9 
± 4.5 mmol, respectively. The 8-week change in sodium was –17.7 ± 15.0 mmol/L for 
concentrated fermented milk based ltp, –9.2 ± 10.8 mmol/L for enzymatic ltp, –2.3 ± 
14.3 mmol/L for synthetic ltp and +3.9 ± 16.0 mmol/L for placebo. For potassium 8-week 
changes were –8.8 ± 5.4, –0.2 ± 5.8, –14.0 ± 4.7, and –3.8 ± 7.0 mmol/L, respectively. 
Changes in sodium and potassium did not significantly differ between treatment and 
placebo (all P >0.1).
Mean baseline ace-activity (±se) was 30.0 ± 0.7 U/L and remained constant during the 
study (Table 4.4). Baseline plasma angiotensin II concentration was 10.4 ± 0.5 pmol/L 
and decreased slightly in the concentrated fermented milk based ltp group and in the 
enzymatic ltp group during intervention, but this was not significantly different from 
placebo (Table 4.4).
Table 4.3  Office blood pressure during intervention in 135 subjects 
with untreated elevated blood pressure, by treatment 
Outcome Fermented ltp1 Enzymatic ltp Synthetic ltp Placebo
 (n = 35) (n = 32) (n = 36) (n = 32)
Systolic bp, mm Hg
 Baseline
 Week 84
 Change4
 Change attributed to  
 treatment, mean difference  
 (95% ci), P-value
Diastolic bp, mm Hg
 Baseline
 Week 84
 Change4
 Change attributed to  
 treatment, mean difference  
 (95% ci), P-value
140.7 ± 2.3
136.5 ± 2.3
–4.3 ± 1.3
83.9 ± 1.3
81.7 ± 1.5
–2.4 ± 0.9
142.2 ± 2.1
138.8 ± 2.4
–2.8 ± 1.7
1.6 (–3.9, 6.9)
P = 0.83
81.9 ± 1.8
79.9 ± 2.0
–2.4 ± 1.1
–0.01 (–3.4, 3.4)
P = 1.00
141.6 ± 2.4
136.8 ± 2.7
–4.8 ± 1.8
–0.5 (–6.0, 5.0)
P = 0.99
85.5 ± 1.9
83.0 ± 1.9
–2.4 ± 0.9
0.01 (–3.4, 3.5)
P = 1.00
1 ltp indicates lactoptripeptides (ipp and vpp). 
2 Values are mean (±se).
3 2-sided P values for the difference from placebo (Dunnett test).
4 Missing for 2 subjects (1 synthetic ltp, 1 placebo).
142.0 ± 1.92
140.4 ± 2.2
–1.6 ± 1.5
2.8 (–2.6, 8.2)
P = 0.473
83.2 ±  1.4
82.9 ±  1.4
–0.3 ±  1.0
2.2 (–1.2, 5.5)
P = 0.30
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Plasma glucose, liver enzymes, indicators of renal function, and hematology were 
similar in the 4 groups and did not change significantly during the study (data not 
shown). During the 8 weeks of treatment a few minor adverse events were recorded, but 
there were no differences according to treatment.
post-hoc analysis
In 59 subjects with a dairy calcium intake <726 mg/d the change in blood pressure was 
–3.2/–1.6 mm Hg for all ltp treatments combined versus –5.8/–2.7 mm Hg for the 
placebo group. In 59 subjects with a higher calcium intake, values were –3.3/–1.7 mm 
Hg and –3.6/–1.8 mm Hg, respectively. In subjects with a low dairy protein intake (<24 
g/d), corresponding values were –3.2/–1.3 mm Hg for ltp versus –6.8/–3.4 mm Hg for 
placebo, and in subjects with a higher dairy protein intake –3.3/–2.0 mm Hg and 
–2.6/–1.0 mm Hg, respectively. Probability values for all comparisons were >0.2. 
Table 4.4  Plasma ace-activity and angiotensin ii concentration in 135 subjects 
with untreated elevated blood pressure, by treatment 
Outcome Fermented ltp1 Enzymatic ltp Synthetic ltp Placebo
 (n = 35) (n = 32) (n = 36) (n = 32)
ace-activity, u/l
 Baseline1
 Week 82
 Change2 
 Change attributed to 
 treatment, mean difference 
 (95% ci), P-value
Angiotensin ii, pmol/l
 Baseline3 
 Week 84 
 Change5
 Change attributed to 
 treatment, mean difference 
 (95% ci), P-value
29.2 ± 1.1
28.7 ± 1.1
–0.3 ± 0.5
9.8 ± 1.0
8.8 ±  0.6
–0.5 ± 1.0
30.9 ± 1.4
30.7 ± 1.4
–0.1 ± 0.4
0.2 (–1.4, 1.8)
P = 0.98
9.5 ± 0.7
9.1 ± 0.5
–0.3 ± 0.7
0.2 (–2.7, 3.1)
P = 1.00
29.1 ± 1.2
29.4 ± 1.1
0.3 ± 0.4
0.6 (–1.0, 2.2)
P = 0.65
10.2 ± 1.0
8.9 ± 0.6
–1.6 ± 0.8
–1.1 (–4.2, 2.0)
P = 0.73
ltp indicates lactoptripeptides (ipp and vpp); Values are mean (±se); 2-sided P values for the difference 
from placebo (Dunnett test).
1 Missing for 2 subjects (1 synthetic ltp, 1 placebo).
2 Missing for 4 subjects (1 synthetic ltp, 3 placebo).
3 Missing for 3 subjects (1 enzymatic ltp, 1 synthetic ltp, 1 placebo); values below detection limit for 10 subjects 
 (2 fermented ltp, 3 enzymatic ltp, 3 synthetic ltp, 2 placebo).
4 Missing for 5 subjects (2 synthetic ltp, 3 placebo); values below detection limit for 11 subjects 
 (5 fermented ltp, 3 enzymatic ltp, 2 synthetic ltp, 1 placebo).
5 Missing for 6 subjects (1 enzymatic ltp, 2 synthetic ltp, 3 placebo); values below detection limit for 16 subjects 
 (5 fermented ltp, 5 enzymatic ltp, 3 synthetic ltp, 3 placebo).
30.5 ± 1.5
30.6 ± 1.5
0.1 ± 0.5
0.4 (–1.2, 2.0)
P = 0.86
12.2 ± 1.0
9.6 ± 0.8
–3.4 ± 0.9
–2.9 (–5.8, 0.1)
P = 0.06
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Discussion
This trial showed no antihypertensive effect of the dairy peptides ipp and vpp that were 
generated by concentrating fermented milk, enzymatic hydrolysis, or chemical synthesis 
in 135 subjects with high normal and elevated blood pressure. Although sbp and dbp 
decreased during the study, this was not attributable to effects of ipp and vpp. The 
results were consistent for office, home and ambulatory blood pressure. 
Strengths of this study are its randomized double-blind placebo-controlled design. In 
addition, compliance was excellent and only 1 subject dropped out. Data were analyzed 
according to the intention-to-treat principle. Restricting the analysis to compliant 
subjects yielded similar results. Baseline characteristics, including initial levels of blood 
pressure, were similar among the 4 groups. Subjects were also able to maintain their 
habitual level of exercise and dietary pattern during the study, as confirmed by their 
unchanged body weight and urinary excretion of sodium and potassium. 
From most trials in humans it was concluded that ipp and vpp are effective in lowering 
blood pressure6-14. In the majority of studies milk fermented with Lactobacillus helveticus 
was examined in subjects with high normal blood pressure or mild hypertension. The 
effect on blood pressure, either office, home, or abpm, ranged from –1.5 to –11.0 mm Hg 
for sbp and from –0.5 to –6.8 mm Hg for dbp compared with placebo6-8, 10, 12-14. Also, ipp 
and vpp obtained by enzymatic hydrolysis of casein, using Aspergillus oryzae protease, 
have been shown to lower blood pressure in mild hypertensives9, 11. We considered 
several possible explanations for the absence of an antihypertensive effect of ipp and 
vpp in our study. Previous studies that did show an effect had a duration of 4 to 21 
weeks and daily doses of ipp and vpp between 2.5 and 52.5 mg. Hence, we conclude that 
our intervention of 8 weeks with a dose of 14 mg ltp equivalents, containing 4.2 to 5.4 
mg ipp and 5.0 to 5.8 mg vpp, should have been sufficient for detecting any effect on 
blood pressure, if present. Also, the contrast in ace-inhibitory capacity between the 
treatment drinks and the placebo should have been sufficient in our study. Secondly, 
ltp may exert their effect only in subjects with clinically established hypertension. 
Ninety percent of our subjects had a blood pressure in the high-normal or mildly 
hypertensive range, after repeated measurements. Some studies that were positive for 
ltp had higher blood pressure levels at baseline7, 12, 14. It should also be noted that in 
most studies, despite randomization, initial blood pressure was higher in the 
intervention than in the control group7, 8, 10, 12, 14. As a result, blood pressure effects 
attributed to ipp and vpp may have been overestimated. Thirdly, we considered the role 
of background diet. Our Dutch study population already had a high habitual intake of 
dairy foods (520 g per day) and calcium from dairy (820 mg per day). Previous studies 
were almost exclusively performed in Japanese and Finnish subjects, with different 
dietary patterns. In a post-hoc analysis we examined whether a low or high habitual 
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intake of dairy protein and calcium could modify blood pressure response to ltp, but 
this was not the case. Finally, because our subjects were asked to maintain their regular 
lifestyle or dietary pattern during the study, we cannot exclude a possible beneficial 
effect of ltp in combination with favorable lifestyle or dietary changes, although we 
consider this unlikely.
The putative antihypertensive effect of dairy peptides has been related to ace-
inhibition17, 19-21, but we found no consistent changes in plasma ace-activity or 
angiotensin ii. The potency of ace-inhibition of most food-derived peptides in vitro 
ranges from 2 to 1000 µmol/L, which is over 1000 times weaker than antihypertensive 
drugs22. Such effects in vivo may not have been detectable in our study due to large 
inter- and intraindividual variation. We did not examine other mechanisms of 
antihypertensive action, such as a direct relaxation of vascular muscle cells or opioid or 
antioxidant activities23.
In conclusion, the present randomized double-blind controlled trial provides no 
evidence for a blood pressure lowering effect of the lactotripeptides ipp and vpp in 
human subjects with untreated elevated blood pressure. 
Perspectives
There is growing interest in the role of low-fat dairy for the prevention of hypertension. 
A new line of research in this field focuses on bioactive peptides derived from milk 
proteins (e.g., ipp and vpp) that could inhibit the angiotensin-converting enzyme (ace). 
Previous studies identified ipp and vpp as promising food ingredients for blood pressure 
control in mildly hypertensive subjects6-14. The present double-blind, randomized 
controlled trial in 135 Dutch subjects with elevated blood pressure, however, provides 
no evidence for an antihypertensive effect of ipp and vpp. More well-conducted trials in 
different populations are needed to see whether supplementation with dairy peptides 
could have a place in the treatment of mild hypertension.
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Supplemental table 4.1  Response in home blood pressure after 8 weeks of intervention 
in 128 subjects with untreated elevated blood pressure, by treatment 
 Fermented ltp Enzymatic ltp Synthetic ltp Placebo
 (n = 35) (n = 32) (n = 34) (n = 27) 
Systolic bp, mm Hg
Morning1
 8-week change
 Change attributed to 
 treatment (95% ci), P-value
Noon2
 8-week change
 Change attributed to 
 treatment (95% ci), P-value
Evening3
 8-week change
 Change attributed to 
 treatment (95% ci), P-value
Diastolic bp, mmHg
Morning1
 8-week change
 Change attributed to 
 treatment (95% ci), P-value 
Noon2
 8-week change
 Change attributed to 
 treatment (95% ci), P-value
Evening3
 8-week change
 Change attributed to 
 treatment (95% ci), P-value
–0.8 ± 2.1
–1.2 ± 2.1
–3.2 ± 2.4
0.1 ± 1.5
–0.4 ± 1.4
–1.3 ± 1.4
–0.8 ± 1.6
0.1 (–5.5, 5.7)
P = 1.00
–1.6 ± 1.6
–0.4 (–6.1, 5.2)
P = 1.00
–3.3 ± 2.2
–0.1 (–7.6, 7.3)
P = 1.00
–1.0 ± 1.3
–1.2 (–5.2, 2.8)
P = 0.82
–0.6 ± 1.2
–0.2 (–4.2, 3.7)
P = 1.00
–2.2 ± 1.4 
–0.9 (–5.5, 3.8)
P = 0.94 
–4.4 ± 1.6
–3.5 (–9.2, 2.1)
P = 0.31
–2.0 ± 1.4
–0.8 (–6.5, 4.9)
P = 0.97
–5.6 ± 2.0
–2.4 (–9.9, 5.1)
P = 0.78
–2.1 ± 0.9
–2.2 (–6.3, 1.8)
P = 0.40
–1.5 ± 1.0
–1.1 (–5.1, 2.9)
P = 0.85
–3.0 ± 1.3
–1.7 (–6.4, 3.0)
P = 0.73
ltp, lactoptripeptides (ipp and vpp). Values are mean (±se); two-sided P-values for the difference 
from placebo (Dunnett’s test).
1 Missing for 1 subjects in the placebo group.
2 Missing for 3 subjects (1 enzymatic ltp, 1 synthetic ltp, 1 placebo).
3 Missing for 2 subjects (1 synthetic ltp, 1 placebo).
–1.0 ± 1.4
–0.1 (–5.7, 5.5)
P = 1.00
–3.5 ± 1.5
–2.3 (–7.9, 3.3)
P = 0.62
–5.2 ± 2.0
–2.0 (–9.3, 5.4)
P = 0.85
–0.3 ± 1.0
–0.4 (–4.3, 3.6)
P = 0.99
–2.2 ± 1.1
–1.9 (–5.8, 2.1)
P = 0.52
–1.6 ± 1.2
–0.3 (–4.9, 4.3)
P = 1.00
83Chapter 4  | 
 Lactotripeptides and blood pressure
110
115
120
125
130
135
140
145
150
155
160
165
170
12
:0
0 
P
M
12
:3
0 
P
M
1:
00
 P
M
1:
30
 P
M
2:
00
 P
M
2:
30
 P
M
3:
00
 P
M
3:
30
 P
M
4:
00
 P
M
4:
30
 P
M
5:
00
 P
M
5:
30
 P
M
6:
00
 P
M
6:
30
 P
M
7:
00
 P
M
7:
30
 P
M
8:
00
 P
M
8:
30
 P
M
9:
00
 P
M
9:
30
 P
M
10
:0
0 
P
M
10
:3
0 
P
M
11
:0
0 
P
M
11
:3
0 
P
M
12
:0
0 
A
M
1:
00
 A
M
2:
00
 A
M
3:
00
 A
M
4:
00
 A
M
5:
00
 A
M
6:
00
 A
M
7:
00
 A
M
7:
30
 A
M
8:
00
 A
M
8:
30
 A
M
9:
00
 A
M
9:
30
 A
M
10
:0
0 
A
M
10
:3
0 
A
M
11
:0
0 
A
M
11
:3
0 
A
M
Time
A
m
b
u
la
to
ry
 s
ys
to
lic
 B
P
 (
m
m
H
g
)
Fermented LTP
Enzymatic LTP
Synthetic LTP
Placebo
 
A
m
bu
la
to
ry
 s
ys
to
lic
 b
p 
(m
m
 H
g)
170
165
160
155
150
145
140
135
130
125
120
115
110
Time
12
.0
0 
PM
12
.3
0 
PM
1.
30
 P
M
1.
00
 P
M
1.
30
 P
M
2.
00
 P
M
2.
30
 P
M
3.
00
 P
M
3.
30
 P
M
4.
00
 P
M
4.
30
 P
M
5.
00
 P
M
5.
30
 P
M
6.
00
 P
M
6.
30
 P
M
7.
00
 P
M
7.
30
 P
M
8.
00
 P
M
8.
30
 P
M
9.
00
 P
M
9.
30
 P
M
10
.0
0 
PM
10
.3
0 
PM
11
.0
0 
PM
11
.3
0 
PM
12
.0
0 
AM
1.
00
 A
M
2.
00
 A
M
3.
00
 A
M
4.
00
 A
M
5.
00
 A
M
6.
00
 A
M
7.
00
 A
M
7.
30
 A
M
8.
00
 A
M
8.
30
 A
M
9.
00
 A
M
9.
30
 A
M
10
.0
0 
AM
10
.3
0 
AM
11
.0
0 
AM
11
.3
0 
AM
ermented ltp 
nzymatic ltp 
ynthetic ltp 
lacebo
Supplemental figure 4.1  24-hour curves for ambulatory systolic blood pressure at week 8 in 
a subgroup of 58 randomized subjects in the three treatment groups and the placebo group.
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Supplemental figure 4.2  24-hour curves for the 8-week change in systolic blood pressure in a 
subgroup of 58 randomized subjects in the three treatment groups and placebo group. 
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A very high intake of conjugated linoleic acid, a natural trans fat 
from milk and meat, does not affect blood pressure in normotensive 
human subjects
Mariëlle F Engberink, 
Johanna M Geleijnse, 
Anne J Wanders, 
Ingeborg A Brouwer
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Abstract
Background: Cis-9, trans-11 conjugated linoleic acid (cla) is a natural trans fatty acid 
that is largely restricted to ruminant fats and is consumed in foods and supplements. 
Its role in blood pressure regulation is still unclear. Therefore, our objective was to 
study the effect of cis-9, trans-11 cla on blood pressure compared to oleic acid.
Methods: Sixty-one healthy men (n = 25) and women (n = 36) were sequentially fed each 
of 3 diets for 3 weeks, in random order, for a total of 9 weeks. Diets were identical except 
for 7% of energy (18.9 g in a diet of 10 mj/day) which was provided either by oleic acid, 
by industrial trans fatty acids, or by cis-9, trans-11 cla. We measured blood pressure 
and heart rate on days 19 and 21 (period 1), days 40 and 42 (period 2) and days 61 and 
63 (period 3). 
Results: At baseline, mean blood pressure was 113.8 ± 14.4 mm Hg systolic and 66.3 ± 
9.6 mm Hg diastolic. The effect of the cla diet compared to the oleic acid diet was +0.11 
mm Hg (95% confidence interval: –1.27, 1.49) for systolic  blood pressure and –0.45 mm 
Hg (–1.63, 0.73) for diastolic blood pressure. After the industrial trans fatty acid diet, 
the blood pressure effect was +1.13 mm Hg (–0.25, 2.51) systolic and –0.44 mm Hg 
(–1.62, 0.73) diastolic compared to the oleic acid diet.
Conclusion: High intakes of cis-9, trans-11 cla do not affect blood pressure in healthy 
normotensive subjects. 
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Introduction
Cis-9, trans-11 conjugated linoleic acid (cla) is a natural trans fatty acid that is produced 
in the rumens of cows, sheep and other ruminant animals through partial hydrogenation 
of unsaturated fatty acids from the feed by bacteria. It can also be formed from vaccenic 
acid in animals and in humans1. It is consumed by humans in foods and as supplements. 
In general, supplements consist of 50:50 mixtures of the isomers cis-9, trans-11 cla and 
trans-10, cis-12 cla or mixtures of more isomers, while cla in dairy products consists 
of over 90% of the cis-9, trans-11 cla isomer.
cla has attracted much interest since favorable effects on health, e.g. weight reduction, 
improved insulin sensitivity and improved blood lipid profiles have been reported in 
animal studies2. In addition, cla was found to lower blood pressure in several rat 
models3-5. On the other hand, cla is a trans fatty acid and harmful effects in the 
cardiovascular system cannot be excluded. Little is known about the effect of cla on 
human blood pressure. To our best knowledge, only a few blood pressure trials have 
been done with different mixtures of cla, all of which had a parallel controlled design. 
Raff et al. examined the effect of a 5-week diet supplemented with 4.7 gram of a 50:50 
mixture of cis-9, trans-11 cla and trans-10, cis-12 cla, or a diet low in cla, on blood 
pressure and isobaric arterial elasticity in 60 healthy, non-hypertensive young men6. 
Systolic blood pressure non-significantly increased by 3 mm Hg in the cla group 
compared to the control group (p-value: 0.07), whereas diastolic blood pressure did not 
change. Laso et al. studied effects of a 12-week daily intervention with 3 grams of a 
mixture of multiple cla isomers or placebo in 60 overweight and obese individuals 
with a mean blood pressure of 147/84 mm Hg and found no effect on blood pressure7. 
Additionally, Iwata et al. did a 12-week trial with a daily intake of 3.4 gram cla mixture 
in 60 healthy overweight Japanese male volunteers and also found no effect of cla on 
blood pressure8. 
We conducted a randomized cross-over study to examine the effect of a high dose of 
cis-9, trans-11 cla, from an 80:20 mixture, on blood pressure in 61 normotensive 
healthy Dutch subjects. The blood pressure effect of cla was compared to that of 
industrial trans fatty acids and oleic acid, and dietary intakes were fully controlled 
during the 9-week intervention period.
Subjects and Methods
The present study formed part of a larger trial that was set up to examine the effect of 
cis-9, trans-11 cla on cardiovascular health (Wanders et al. submitted for publication). 
Here, we describe the effect of cis-9, trans-11 cla on blood pressure, which was a pre-
specified secondary endpoint of the study.
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Subjects
The Medical Ethics Committee of Wageningen University approved the study. We 
recruited men and women aged 18 to 65 y from the Dutch population (Wageningen 
area) through advertisements. Potential subjects gave written informed consent before 
screening. We excluded subjects with glycosuria or proteinuria in morning urine 
samples, and with concentrations of total cholesterol >6.5 mmol/L or triglycerides >2.3 
mmol/L. Subjects were also excluded if they suffered from diabetes mellitus or 
cardiovascular diseases, if they used cholesterol-lowering or anti-hypertensive 
medication, had unusual dietary habits including high alcohol intakes, had a bmi >30 
kg/m2, or were pregnant or lactating. 
Design and randomization procedure
We performed a randomized multiple cross-over controlled feeding trial with three 
consecutive periods lasting three weeks each. The trial ran for 9 weeks in total, from 
September 25 to November 27, 2007. Before a 2-day run-in period, we randomly assigned 
subjects to one of the six possible diet sequences by computer-generated numbers. We 
performed blood pressure measurements and drew blood samples during a pre-trial 
screening visit, on two days at the end of each intervention period, and 3 weeks after 
the end of the study.
Diets and study procedures
All subjects received diets with the same composition but in different amounts 
depending on their energy requirement. On week days during lunch time, subjects 
consumed a hot meal at the Division of Human Nutrition of Wageningen University. All 
other food was provided daily to take away for consumption at home. Foods for the 
weekend and instructions for its preparation were provided each Friday. The supplied 
foods provided 90% of each subject’s energy requirement. For the remaining 10% of 
energy, subjects had to select foods from a list of foods and drinks that were low in fat. 
Subjects recorded the selected foods daily in a diary, as well as any deviations from the 
diet, illnesses, and use of medication. Subjects were asked to maintain their usual 
lifestyle and were not allowed to drink fortified fruit juices, unfiltered coffee (containing 
cafestol), or to eat more than 10 pieces of liquorices a day, as the latter may affect blood 
pressure. We weighed subjects twice a week and adjusted energy intake when necessary 
in order to maintain stable body weight.
Experimental fats
The diets were intended to contain the same nutrients except for 7% of total energy, 
which came from special oils and fats containing cis-9, trans-11 cla, industrial trans 
fatty acids or oleic acid. cla was provided by a cla-rich oil (donated by Lipid Nutrition, 
Wormerveer, the Netherlands). Margarines and yogurt drinks enriched with the special 
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oils and fats according to our specifications were manufactured by nizo Food Research 
(Ede, the Netherlands). The fat in the oleic acid margarine consisted of 82% high-oleic 
sunflower oil (Aldoc bv, Schiedam, the Netherlands) and 18% of a standard hard stock, 
an interesterified mixture of palm oil and palm kernel fat (Unilever Research & 
Development, Vlaardingen, the Netherlands). The fat in the cla margarine contained 
25% cla-rich oil, 10% sunflower oil, 47% high-oleic sunflower oil and 18% standard hard 
stock. The fat of the industrial trans margarine consisted of 65% partially hydrogenated 
vegetable fat (Melano, fuji Oil Europe, Ghent, Belgium), 10% sunflower oil and 25% 
high-oleic sunflower oil. In addition, yogurt drinks were produced by enriching fat-free 
yogurt with 5 grams of high oleic sunflower oil, 5 grams of cis-9, trans-11 cla-rich oil or 
5 grams of partially hydrogenated vegetable fat per 100 mL, respectively. The margarines 
were used as a spread, and as an ingredient in bread, cookies, sauces, and gravies. Other 
food items were bought commercially. Subjects were not informed about the type of 
diet they consumed until completion of data analysis.
Diet composition
Duplicate diets were analyzed for protein, dry matter, ash, dietary fiber and digestible 
carbohydrates9-11. cla isomers were separated by gas chromatography on a Sil-88 column 
and other fatty acids on a wax-58 column (Varian, Middelburg, the Netherlands). The 
composition of the free-choice items was calculated with use of Dutch food composition 
tables (nevo, 2006) and included in the calculation of the average daily intake of 
nutrients. 
Blood pressure measurements
Four trained staff members measured blood pressures at the study center during a 
pre-trial screening visit, on days 19 and 21 (period 1), days 40 and 42 (period 2), days 61 
and 63 (period 3), and 21 days after the end of the study. After a 10-minute rest, 3 blood 
pressure measurements with 2 minute intervals were performed on the dominant arm 
in sitting position, using a validated automatic blood pressure device (Omron hem-907) 
with an appropriately sized cuff. The first measurement was discarded and the 
subsequent two measurements were averaged. Measurements were repeated after 2 
days and values of both occasions were averaged. All blood pressure measurements 
were performed between 7 and 9:30 am at a fixed time using the same device by the 
same staff member for each individual. Subjects remained blinded toward all blood 
pressure values until data-analysis was completed.
Other measurements
Blood samples were taken during the pre-trial screening visit and during the intervention 
on the same occasions when blood pressure measurements took place. Venous blood 
was collected by nurses after an overnight fast, and all samples were taken at the same 
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time of the day to minimize within-subject variation. The blood samples were directly 
processed and stored at –80°C. The samples were analyzed for blood lipoproteins, as 
reported elsewhere (Wanders et al., submitted for publication). 
Compliance to the diet was assessed by checking the diaries and by examining the fatty 
acid composition of cholesterylesters in plasma. The fatty acids in plasma 
cholesterylesters were analyzed as described previously12. The results were combined 
and expressed as a proportion by weight of all fatty acids detected.  
Statistical analysis
Double data entry was performed and discrepancies were solved. Treatment codes were 
broken after blind data analysis. 
Values reported in text and tables are means with standard deviations (sd) or 95% 
confidence intervals (95% ci), unless stated otherwise. Response to treatment was 
defined as the difference in systolic blood pressure between the diets. Data were 
analyzed using the linear mixed model where homogeneous Compound Symmetry (cs) 
was selected as the covariance structure. Changes in blood pressure values were tested 
for treatment-, period- and carry-over effect; the latter one was tested by introducing a 
period by treatment interaction term. The lsd (Least Significant Difference) test  was 
used for pairwise comparisons. 
All analyses were performed with spss version 15.0 (spss, Chicago, Illinois, United 
States). Differences were considered statistically significant when p <0.05 (two-sided). 
Table 5.1  Baseline characteristics of 61 healthy Dutch 
subjects who completed the study on cla and blood pressure
Characteristic
Age, y
Sex, n (% male)
Current smokers, n (%)
bmi, kg/m2
Total serum cholesterol, mmol/L
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
Heart rate, bpm
Values are presented as means ± sd or numbers (percentages). 
30.9 ± 13.7
25 (41)
4 (6.6)
22.8 ± 3.2
4.54 ± 0.77
113.8 ± 14.4
66.2 ± 9.6
73.3 ± 12.4
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Results
Subjects
We enrolled 63 subjects in the trial. Two subjects withdrew from the trial; one man 
after 6 days because of personal reasons and one woman after 20 days due to illness, 
both not related to the study. Figure 5.1 shows the number of subjects screened, 
excluded and randomized. The screening characteristics of the subjects who completed 
the study are shown in Table 5.1.
Figure 5.1 Flow chart of a randomized multiple cross-over trial of cis-9, trans-11 cla and blood pressure 
in 61 normotensive Dutch subjects. Each intervention period lasted 3 weeks. 
cla indicates Conjugated Linoleic Acid; O, Oleic acid diet; I, Industrial trans fatty acids diet; C, cis-9, trans-11 cla diet.
* 2 subjects discontinued the intervention due to personal reasons (n = 1) and illness (n = 1) unrelated to the trial. 
These subjects were not included in the analysis.
Completed
trial (n = 11)
Allocated to 
o-i-c (n = 11)
Completed
trial (n = 10)
Allocated to 
o-c-i (n = 10)
Completed
trial (n = 9)*
Allocated to 
i-o-c (n = 11)
Completed
trial (n = 10)
Allocated to 
i-c-o (n = 10)
Completed
trial (n = 11)
Allocated to 
c-i-o (n = 11)
Completed
trial (n = 10)
Allocated to 
c-o-i (n = 10)
63 Randomized
 25 excluded:
Withdrew before screening (n = 9)
Elevated lipid levels (n = 3)
High bmi (n = 2)
Unusual dietary habits (n = 2)
Other reasons (n = 5)
Excluded by lottery (n = 4)
88 volunteers assessed for eligibility
Diets and dietary adherence
Mean daily intakes of energy and nutrients according to chemical analysis of the three 
experimental diets plus calculations from free-choice items are presented in Table 5.2. 
Intake of total energy, protein and carbohydrates were similar on all three diets, as were 
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intake of total fat, dietary fiber and alcohol. The cholesterylesters of all subjects showed 
that the cla proportion was 3.1 times higher after the cis-9, trans-11 cla diet than after 
the oleic acid diet (p <0.001).
Diaries kept by the subjects revealed only minor deviations from the protocol. Six 
subjects reported nausea for 1 or 2 days on the cis-9, trans-11 cla and industrial trans 
fatty acids diets, and 2 while on the oleic acid diet. Three subjects reported diarrhea for 
1-2 days while on the cis-9, trans-11 cla diet.
Blood pressure 
At baseline, mean blood pressure was 113.8 ± 14.4 mm Hg systolic and 66.3 ± 9.6 mm 
Hg diastolic. Table 5.3 presents the average blood pressure and heart rate at the end of 
each dietary intervention period. We observed no significant differences in blood 
Table 5.2  Mean daily intakes of energy and nutrients per diet1  
Energy intake, mj/d 
Energy intake, Kcal/d
Fat, % of energy
 Saturated fatty acids 
  C12:0 (lauric)
  C14:0 (myristic)
  C16:0 (palmitic)
  C18:0 (stearic)
 Total cis fatty acids 
  Cis-9 C18:1 (oleic)
  Cis-9,cis-12 C18:2 (linoleic)
 Total trans fatty acids 
  Total trans C18:1 
  Trans-9 C18:1 (elaidic)
  Trans-10 C18:1
  Trans-11 C18:1 (vaccenic)
  Total cla 
   Cis-9, trans-11 cla 
   Trans-10 ,cis-12 cla
Protein, % of energy
Carbohydrates, % of energy
Alcohol, % of energy
Dietary fiber, g/mj
Cholesterol, mg/mj
cis-9, trans-11 cla   
diet
10.7
2553
39.7
11.3
0.8
1.1
6.3
1.9
17.7
13.4
3.4
9.1
<0.1
<0.1
<0.1
<0.1
9.0
6.9
1.5
12.8
46.0
1.5
2.9
21.9
Industrial trans  
diet
10.8
2568
40.1
13.8
0.2
0.7
9.7
2.3
17.1
11.3
4.1
7.5
7.3
3.1
1.5
0.8
0.1
0.1
0.0
11.8
46.7
1.4
2.9
22.8
Oleic acid 
diet
10.6
2532
39.7
10.5
0.7
0.9
5.7
2.0
27.4
23.1
3.2
0.2
<0.1
<0.1
<0.1
<0.1
0.1
0.1
0.0
12.6
46.3
1.4
3.0
22.3
cla indicates Conjugated Linoleic Acid. 
1  According to chemical analysis of duplicates of the diets (based on 3 samples per diet); contributions from 
free-choice items were included as described in Methods.
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pressure or heart rate among the diets. The effect on blood pressure of the cis-9, trans-11 
cla diet compared to the oleic acid diet was +0.11 (–1.27, 1.49) mm Hg systolic and 
–0.45 (–1.63, 0.73) mm Hg diastolic. After the industrial trans fatty acids diet, the 
treatment effect compared to the oleic acid diet was +1.13 (–0.25, 2.51) mm Hg for 
systolic blood pressure and –0.44 (–1.62, 0.73) mm Hg for diastolic blood pressure. We 
observed a significant period effect for blood pressure; in the group as a whole systolic 
blood pressure increased by 2.38 (1.00, 3.75) mm Hg (p<0.001). We found no carry-over 
effect for systolic or diastolic blood pressure (p = 0.16 and p = 0.91, respectively).
Table 5.3  Blood pressure and heart rate at the end of the three intervention periods in 61 
healthy men and women, by treatment  
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
Heart rate, bpm
cis-9, trans-11 cla   
diet
113.2 (109.3, 115.0)
65.7 (63.7, 67.7)
70.3 (67.2, 73.5)
Industrial trans  
diet
112.1 (110.3, 116.0)
65.7 (63.7, 67.7)    
70.7 (67.5, 73.9)
Oleic acid 
diet
113.3 (110.5, 116.1)
65.3 (63.3, 67.3)
70.4 (67.2, 73.6)
cla indicates Conjugated Linoleic Acid. Values are mean (95% ci); data were analyzed using the linear mixed model 
where homogeneous Compound Symmetry (cs) was selected as covariance structure. No significant differences among 
the diets were found.
Other measurements
Body weight did not differ among the three diets. Mean body weight (± sd) was 70.1 ± 
12.2 kg on the oleic acid diet, 70.1 ± 12.2 kg on the industrial trans fatty acids diet and 
70.1 ± 12.0 kg on the cis-9, trans-11 cla diet. However, over 9-weeks intervention period 
the average body weight of the total group decreased on by 0.6 ± 1.7 kg (p = 0.006).
Discussion
In the present study among 61 healthy normotensive subjects aged between 18 and 65 
y, we found no effect of cis-9, trans-11 cla on blood pressure or heart rate. Also, industrial 
trans fatty acids did not affect blood pressure or heart rate. 
Strengths of the study were its randomized cross-over design and strictly controlled 
food intake, which was confirmed by the fatty acid composition of plasma 
cholesterylesters. We used a strict and standardized protocol for blood pressure 
measurement (e.g. rest, validated device, appropriately sized cuff, blinding). Body 
weight, an important blood pressure determinant, was carefully monitored and was 
similar for the three diets.
The present trial was not primarily designed to investigate effects on blood pressure, 
and could therefore have some limitations. Sample size was calculated to be able to 
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detect an effect on ldl-cholesterol, the primary outcome of the study. Nevertheless, 
power was sufficient to detect small changes in blood pressure: we could have detected 
a difference in systolic blood pressure of 2 mm Hg with a power of 80%. Second, 
although food intake was controlled, subjects were free to use coffee and table salt. 
However, due to the cross-over design the effect of coffee and table salt use is likely to 
be canceled out. Furthermore, it should be noted that blinding of treatment was not 
completely successful. None of the subjects recognized the difference between the cis-9, 
trans-11 cla and the oleic acid diet, but almost all (96%) subjects recognized the 
industrial trans fatty acids diet due to the solid margarine. Yet, as blood pressure was a 
secondary outcome and most subjects were unaware of this aim of the study, it is 
unlikely that awareness of order of the diets has impacted our blood pressure values. 
Another limitation is the relatively short duration of the dietary intervention periods 
(3 weeks each). Significant blood pressure changes with dietary measures, however, 
have been achieved within such a short time period, including the well-known dash 
study where most of the treatment effect was already achieved after 2 weeks of dietary 
intervention13. Remarkably, blood pressure of the group as a whole increased slightly 
but significantly during the 9-week trial (2.4 mm Hg, p <0.001). This is in contrast to 
what is often observed in blood pressure trials. Because blood pressure was a secondary 
outcome, subjects were not focused on lowering their blood pressure. Intentional 
lifestyle or behavioral changes are therefore unlikely and we cannot explain this 
observation. However, because all subjects received the treatments in random order we 
do not think this has influenced the overall outcome of our study. Finally, our subjects 
were young, lean and healthy, and the effects we found in our study may not apply to 
individuals with higher blood pressure levels, e.g. elderly, obese individuals and patients 
with hypertension. 
Up until now, trans fatty acids have not been clearly associated with blood pressure14-17. 
However, most previous studies have focused on industrial trans fatty acids14-17 or cla 
mixtures with a high content of trans-10, cis-12 cla6-8. The trans-10, cis-12 isomer has 
been suggested to have more unfavorable effects on cardiovascular health than cis-9, 
trans-11 cla2, 18. Less was known about the effect of cis-9, trans-11 cla. Although different 
effects of cis-9, trans-11 cla on blood pressure might have been expected, the results 
from our study are in line with previous studies on the effects of industrial trans fatty 
acids and cla mixtures on blood pressure.
Thus, we conclude that the intake of cis-9, trans-11 cla, exclusively found in dairy 
products, does not affect blood pressure in healthy normotensive human subjects.
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The worldwide prevalence of hypertension is increasing rapidly1, which calls for effective 
public health measures. Whether intake of dairy or specific dairy foods could play a role 
in reducing population blood pressure remains to be established. The research described 
in this thesis comprises observational studies and intervention studies. The main 
objectives were [1] to examine the association of (specific types of) dairy intake with 
blood pressure level and incident hypertension in the Netherlands, a country with a 
traditionally high dairy intake, and [2] to assess the blood pressure effect of two dairy 
components that have recently attracted much attention, i.e. lactotripeptides (ipp and 
vpp) and cis-9, trans-11 conjugated linoleic acid (cla). In this chapter the main findings, 
methodological issues and the validity of the studies are discussed for observational 
studies (chapters 2 and 3) and trials (chapters 4 and 5), respectively. This is followed by 
a review of proposed biological mechanisms that may explain an effect of dairy intake 
on blood pressure. Finally, the evidence provided in this thesis is put into public health 
perspective and suggestions for further research are given. 
Main findings
The findings described in this thesis are presented in Table 6.1. Blood pressure level 
showed no consistent association with overall dairy intake or intake of specific dairy 
foods in a cross-sectional analysis that was conducted in a general population of 21,553 
Dutch subjects (morgen study, chapter 2). In longitudinal analysis, however, inverse 
relations of low-fat dairy with incident hypertension were observed, both in 3454 young 
and middle-aged subjects (subcohort of the morgen study, chapter 2) and in 2245 older 
subjects (Rotterdam study, chapter 3). In both studies, the risk of hypertension was 
reduced by ~20% in subjects who consumed more than 150 mL (~1 serving) of low-fat 
dairy per day. Other dairy foods, i.e. fermented dairy, high-fat dairy, milk and milk 
products, and cheese were not consistently associated with risk of hypertension 
(chapters 2 and 3). When focusing on specific dairy components, we found no blood 
pressure effect for lactotripeptides (i.e. ipp and vpp) in an 8-week randomized controlled 
trial in 135 middle-aged Dutch subjects with untreated elevated blood pressure (chapter 
4). Blood pressure was also not affected by high intakes of cis-9, trans-11 cla in a 9-week 
randomized cross-over trial in 61 normotensive young Dutch subjects (chapter 5).
Dairy food intake in relation to blood pressure: methodological issues
A major part of this thesis is based on observational studies that are subject to certain 
limitations. Methodological issues of the morgen study and the Rotterdam study have 
been discussed in the specific chapters (chapters 2 and 3). Some of these aspects are 
highlighted here because of their relevance for the validity of the findings. 
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Table 6.1  Main findings of the studies described in this thesis  
 Dairy intake and blood pressure or hypertension
 Design Exposure Main results 
 Dairy components
Cohort: morgen study
Type: cross-sectional
Population: 21,553 Dutch adults 
aged 20-65y
Endpoint: bp level
(Ch2)
Cohort: subcohort of 
morgen study
Type: prospective
Population: 3454 Dutch adults 
aged 20-65y
Endpoint: 5y incidence of ht
(Ch2)
Cohort: rotterdam study 
Type: prospective
Population: 2245 Dutch adults 
aged ≥55y
Endpoint: 2y and 6y incidence 
of ht
(Ch3)
Type: Parallel rct
Population: 135 adults aged 35-
70y with untreated elevated bp
Intervention: 8-wk intervention: 
200 mL dairy drink with 14 mg 
lactotripeptides or placebo
(Ch4)
Type: Multiple cross-over rct
Population: 61 normotensive 
adults aged 18-60y
Intervention: 3 diets for 3 
weeks: 7en% provided by oleic 
acid, industrial trans fatty acid 
or cla
(Ch5)
Intake of total, low-fat, 
high-fat, and fermented 
dairy, milk and milk 
products, yogurt, and 
cheese.
Intake of total, low-fat, 
high-fat, and fermented 
dairy, milk and milk 
products, yogurt, and 
cheese.
Intake of total, low-fat, 
high-fat, and fermented 
dairy, milk and milk 
products, and cheese.
Lactotripeptides (ipp 
and vpp) obtained 
by fermentation, 
enzymatic hydrolysis, or 
chemical synthesis.
Cis-9, trans-11 conju-
gated linoleic acid (cla)
No consistent relation between overall dairy or intake of 
specific dairy foods with bp level.
Overall: Overall dairy, specific dairy groups and dairy 
products were not clearly related to risk of developing ht.
Low-fat dairy: Multivariate or (95% ci): 1.00, 0.78 (0.61, 
1.00), 0.81 (0.63, 1.03) and 0.82 (0.64, 1.06, P-trend: 0.24) 
in consecutive quartiles of intake.
Overall (2y): Total dairy, milk and milk products were 
inversely associated with ht. Fermented dairy tended to 
be inversely related to risk of ht. No clear association of 
high-fat dairy and cheese with ht.
Low-fat dairy (2y): Multivariate HR (95% ci): 1.00, 0.75 
(0.60, 0.92), 0.77 (0.63, 0.96) and 0.69 (0.56, 0.86, P-trend: 
0.003) in consecutive quartiles of intake.
Overall (6y): Total dairy, milk and milk products were 
inversely associated with ht. No clear association of 
fermented dairy, high-fat dairy and cheese with ht.
Low-fat dairy (6y): Multivariate hr (95% ci): 1.00, 0.86 
(0.72, 1.04), 0.81 (0.67, 0.97) and 0.84 (0.70, 1.01, P-trend: 
0.07) in consecutive quartiles of intake.
Intervention with lactotripeptides did not affect bp 
(p = 0.46). The mean difference (95% ci) in sbp response 
between the treatment and control group: 
2.8 mm Hg (–2.6, 8.2) for fermented lactotripeptides, 
–0.5 mm Hg (–6.0, 5.0) for enzymatic lactotripeptides, 
1.6 mm Hg (–3.9, 6.9) for synthetic lactotripeptides.
High intake of cis-9, trans-11 cla did not affect bp. 
sbp changed –0.1 mm Hg (–1.49, 1.27) compared to 
control treatment (oleic acid) (p = 0.87).
Also industrial trans fatty acids did not affect bp.
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Study design 
The association between dairy intake and blood pressure was examined in the baseline 
dataset of the morgen study, using cross-sectional data (chapter 2). A main drawback 
of this design is that dairy intake and blood pressure were assessed at the same moment 
in time which makes it difficult to address the temporality of the association. It is 
possible that subjects with elevated blood pressure, or otherwise at increased 
cardiovascular risk, changed their overall dairy intake or specific dairy foods (e.g. from 
high-fat to low-fat dairy) upon medical advice. For this reason, we excluded subjects 
with clinically diagnosed hypertension (i.e. using antihypertensive medication) from 
the analysis. Part of the remaining subjects, however, had untreated (pre)hypertension. 
We consider intentional dietary changes in this group unlikely since elevated blood 
pressure is often asymptomatic and advice on dairy products is not common practice 
in the Netherlands. Apart from the cross-sectional analysis, we also examined the 
association between dairy intake and incident hypertension using prospective data of 
the morgen study (chapter 2) and the Rotterdam study (chapter 3). In these studies 
dairy intake was assessed before the diagnosis of hypertension and misinterpretation 
of findings due to (intentional) dietary changes is therefore not an issue.
The ~20% reduced risk for hypertension that we found in the prospective analyses 
(chapters 2 and 3) suggest that low-fat dairy could lower blood pressure. The cross-
sectional data of the morgen study, however, were not in line with this finding, since 
there was no evidence for an association of low-fat dairy intake with blood pressure 
levels (chapter 2). We have no ready explanation for this discrepancy. Apart from chance, 
which can never be excluded in epidemiological studies, it could be speculated that the 
somewhat older age of the prospective cohorts played a role. The cardiovascular system 
becomes less resilient during ageing, and the sensitivity of blood pressure to dietary 
influences, including dairy intake, may have increased. It is also possible that subjects 
who reported low-fat dairy intake during the baseline survey of the morgen study 
actually had a less favorable intake of dairy products in the past (see chapter 1, Figure 
1.1). The baseline blood pressure level, which can be considered a cumulative endpoint 
of past exposure, may still reflect the intake of e.g. high-fat dairy intake earlier in life. 
Changes in the other direction (i.e., from low-fat to high-fat dairy) during the subsequent 
follow-up period are less likely to have occurred, and the associations with incident 
hypertension are probably not distorted by such dietary changes. Finally, there could be 
methodological reasons why prospective and cross-sectional data are in disagreement. 
In a cross-sectional analysis, one attempts to explain between-subject variation, whereas 
in longitudinal analysis the temporal change within a subject is the outcome of interest. 
In case of the latter, much of the within-subject variation (e.g. due to genetic factors) is 
eliminated in the statistical analysis, leaving more room for the detection of weak 
associations with dietary or lifestyle factors (in this case low-fat dairy intake). 
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assessment of dairy intake
In our observational studies (chapters 2 and 3) dairy intake was assessed by a food 
frequency questionnaire that inquired about the consumption of foods and beverages 
over the past year. This is a generally accepted tool for the assessment of habitual diet 
in large-scale epidemiological studies. The 178-item food frequency questionnaire of 
the morgen study (chapter 2) was validated against 12 monthly 24-hour recalls over a 
1-year period and showed a good correlation (r = 0.7-0.8) for milk and milk products2. 
The 170-item food frequency questionnaire used in the Rotterdam study (chapter 3) 
was validated against a 2-week food diary showing a correlation of 0.7 for calcium3. In 
the Netherlands, about 75% of the dairy products are consumed during meals, i.e. at 
fixed moments during the day4, which may have helped participants in recalling their 
dairy intake. Although the absolute amount cannot be assessed accurately by food 
frequency questionnaires, we assume that subjects have been adequately ranked for 
their dairy intake. Some random misclassification of dairy intake, however, is inevitable. 
This would have weakened our associations between dairy intake and hypertension, 
meaning that the observed 20% risk reduction for hypertension with intake of low-fat 
dairy could be an underestimation of the true association. We can also not exclude the 
possibility that weak associations of overall dairy or specific types of dairy with blood 
pressure or hypertension have been missed due to misclassification of intake. 
Differential misclassification of dairy intake is a larger threat to the validity of 
epidemiological studies. Obese individuals in our studies may have underreported total 
food intake, which will also apply to dairy foods. For this reason, we adjusted dairy 
intake for total energy intake according to the residual method5, before dividing the 
study population into quartiles. By expressing dairy intake relative to a subject’s energy 
intake differential misclassification due to underreporting of total food intake was 
probably eliminated to a large extent. Nevertheless, we cannot ignore the fact that 
obese subjects may have differentially underreported (e.g. specifically for high-fat dairy 
products). It should be noted, however, that less than 10% of the participants from the 
morgen study (chapter 2) and the Rotterdam study (chapter 3) was obese. Should 
differential misclassification have occurred, the influence on the outcome of our study 
is likely to be small. 
assessment of blood pressure and hypertension
An individual’s blood pressure varies in different seasons, from day to day, and also 
during the day. Other factors, such as room temperature, blood pressure device, cuff 
size, posture, and a person’s mental and physical state also influence blood pressure. In 
the morgen study (chapter 2) and the Rotterdam study (chapter 3) blood pressure at 
baseline and during follow-up visits was measured twice at each occasion, with a 
random-zero sphygmomanometer, and the average value was used in the analyses. It is 
104 |  Chapter 6
General discussion
likely that random error occurred in the assessment of blood pressure. This may have 
led to imprecision resulting in wider 95% confidence intervals for the association of 
dairy intake with incident hypertension, but it is unlikely to have influenced the 
strength of the association itself. Multiple blood pressure measurements taken at 
different occasions over a longer period of time is the only way to reduce random error, 
but this was not feasible in these large population-based cohort studies.
In our prospective analyses we used incident hypertension as the primary outcome, 
defined as blood pressure ≥140/90 mm Hg or use of antihypertensive medication. Using 
this arbitrary and robust cut-off point has a major disadvantage; much attention is 
paid to small changes around the cut-off point, while changes elsewhere in the 
distribution are ignored. In this way, part of the effect of dairy intake on blood pressure 
will be missed. In other words, the effect of dairy in the pre-hypertensive range, which 
is particularly relevant for primary prevention, remains unknown. Although we lost 
information by dichotomizing blood pressure, we preferred studying incident 
hypertension to blood pressure changes during follow-up to be able to include subjects 
who initiated antihypertensive medication during follow-up in the analysis. In treated 
subjects actual blood pressure levels are obviously influenced by drug use which may 
overrule possible effects of diet. 
Confounding & effect modification
It could be argued that the lower incidence of hypertension in subjects who used low-
fat dairy products may not be attributable to a specific effect of these foods but to 
other aspects of an overall healthier lifestyle that are not (fully) captured by the 
collected information. Important blood pressure determinants for which the analyses 
were not fully controlled included physical activity and the intake of sodium and 
potassium from non-dairy sources. Although we controlled for several foods rich in 
potassium (e.g. bread, fruits, and vegetables), no adjustment was made for whole-grain 
foods. With regard to sodium intake, we adjusted our analyses for bread and meat, but 
not for use of table salt or other salt-rich foods such as soup or pizza. In addition, we 
had incomplete data on physical activity in both cohort studies. In the morgen study 
(chapter 2), data on physical activity were available for only 77% of the cohort. Repeating 
multivariate analysis with additional adjustment for physical activity in subjects with 
complete data, however, did not materially influence the associations of dairy intake 
with blood pressure or hypertension. In the Rotterdam study (chapter 3), data on 
physical activity during follow-up have only recently become available for 38% of the 
subjects that were included in our analysis. Physical activity expressed as met-scores in 
this subgroup was on average 106 hours per week and did not vary with dairy intake; 
102, 109, 108, and 103 hours per week in consecutive categories of dairy intake, 
respectively (P-trend: 0.40). Apart from this, it should be noted that in both our 
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observational studies the lowest category of energy-adjusted dairy, which was used as 
reference, included more men which resulted in higher intakes of total energy, meat, 
bread, and total and saturated fat than in other categories. We performed additional 
analyses stratified by sex, and observed an inverse association between low-fat dairy 
and hypertension both within men and women (chapters 2 and 3). In both observational 
studies the associations of dairy with hypertension appeared to be robust and 
adjustment for many potential confounders did not change the risk estimates. 
We adjusted our analyses for bmi because it is an important blood pressure determinant 
and could act as a confounder, as described previously. We also checked whether bmi 
should be regarded as an effect modifier. In the morgen study (chapter 2) the association 
between low-fat dairy and incident hypertension did not vary by overweight status, but 
in the Rotterdam study (chapter 3) the association was more pronounced in overweight 
individuals. It could be that overweight at older age puts more pressure on the 
cardiovascular system, although this finding could also be due to chance. Finally, as 
dairy intake has been related to weight management and bmi6, body weight could also 
be an intermediate factor. We therefore ran the statistical models with and without 
adjustment for bmi which did not materially affect the risk estimates. Moreover, in the 
prospective part of the morgen study (chapter 2) weight gain was on average 1.5 kg and 
did not vary across categories of dairy intake. In the Rotterdam study (chapter 3) 
additional adjustment for change in body weight did not attenuate the observed 
association between low-fat dairy and risk of hypertension. It is therefore unlikely that 
body weight was an intermediate factor in the association of low-fat dairy with risk of 
hypertension. 
Interpretation and external validity of the observational findings 
The association of dairy intake with blood pressure and hypertension has been 
examined in several populations in Europe (The Netherlands, Spain, France), Iran, and 
the US, as summarized in chapter 1 (Table 1.2.). These studies have been performed in 
children7, young adults8-10, middle-aged adults11-15, and older adults16-18. The average total 
dairy intake of young and middle-aged adults from the morgen study (chapter 2) and 
older adults from the Rotterdam Study (chapter 3) was 350-400 mL (~2.5 servings), 
ranging from less than 1 serving/d in the lowest category to ~5 servings/d in the highest 
category of dairy intake. In another Dutch cohort of 2064 men and women aged 50-70 
y (Hoorn study), the average total dairy intake was somewhat higher (~4 servings/d)17. 
The range of dairy intake in our cohort studies was more or less similar to that of other 
middle-aged and older populations in Spain8 and the us13, 15, 18 (i.e. 110 to 900 g/d), while 
the range of intake in two French populations was smaller (i.e. 80 to 400 g/d)12, 14. The 
dataset of the morgen study (chapter 2) was sufficiently large to allow a more detailed 
examination of dairy and blood pressure within subjects who had the lowest intake (i.e. 
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bottom quintile of the distribution, range of total dairy intake 0-185 g/d), but no 
associations with blood pressure were found within this low range of intake.
 
Previous observational studies generally suggested an inverse association between 
dairy food intake and blood pressure or hypertension (Table 1.2.), but findings are not 
conclusive. First, beneficial effects were mainly found for low-fat rather than high-fat 
dairy products in some studies8, 15, 18 (chapter 2 and 3), while this was not confirmed by 
others7, 9, 16, 17. In about half of the studies, the association of specific products (e.g. 
cheese, desserts, yogurt) with blood pressure or hypertension was examined9, 10, 14-17, but 
no consistent relationships emerged from these data. Second, significant associations 
in some studies were only observed in subgroups, such as overweight individuals9 or 
men12. In our own studies, we observed an inverse association between low-fat dairy 
and incident hypertension (chapters 2 and 3), whereas dairy intake appeared not to be 
related to blood pressure level (diastolic blood pressure decreased ~1 mm Hg, while 
systolic blood pressure increased ~1 mm Hg, chapter 2). This is in contrast to other 
studies where dairy intake was inversely related to systolic but not diastolic blood 
pressure13, or to blood pressure level but not to change in blood pressure12, 16, 17. Finally, 
while previous observational studies generally observed a ‘dose-response relation’ 
between dairy intake and risk of hypertension, we found indications for a ‘threshold 
effect’. Based on these inconsistencies, we conclude that chance or other phenomena, 
such as publication bias, may have played a role in this field of observational research.
Dairy components and blood pressure: methodological issues
For answering the research questions on dairy components and blood pressure, we 
made use of the randomized trial design. Important methodological issues, e.g. 
randomization, blinding, and compliance, have been discussed in the specific chapters 
(chapters 4 and 5). Here we limit our reflections to more general aspects of blood 
pressure trials and possible effects unrelated to the intervention.
Study population
The trial on lactotripeptides (chapter 4) was set up to study blood pressure effects in 
untreated hypertensive subjects. Well-known phenomena in blood pressure research 
are ‘white-coat hypertension’ and ‘regression-to-the-mean’1. To ensure inclusion of truly 
hypertensive subjects and to reduce the possibility of ‘regression-to-the-mean’ during 
the intervention period, we applied strict measurement conditions in a comfortable 
non-clinical environment at several screening occasions over time. Indeed, blood 
1 Regression to the mean is a statistical phenomenon that can make a natural variation in repeated data look like a real 
change. It happens when usually large or small measurements tend to be followed by measurements that are closer to the 
mean19.
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pressure showed a huge decline during the screening phase and over 65% of the 
screened subjects could not be enrolled because systolic blood pressure dropped below 
140 mm Hg. Blood pressure further dropped during the 2-week run-in phase, leaving 
only 74 subjects (55% of those enrolled) with a systolic blood pressure above 140 mm 
Hg at the start of the trial. Should only truly hypertensive subjects be susceptible to a 
blood pressure lowering effect of lactotripeptides, it could be possible that we missed 
an effect in our trial since only 10% of our study population had moderate to severe 
hypertension. 
In the trial on cis-9, trans-11 cla (chapter 5) blood pressure was a secondary outcome. 
Subjects using antihypertensive medication were not allowed to participate, but other 
exclusion criteria that may be relevant when studying blood pressure (e.g. age, bmi, 
initial blood pressure) were not applied. As a result, the trial was conducted in young 
and lean, healthy subjects with normal blood pressure levels (mean systolic blood 
pressure 114 mm Hg) which puts restrictions on the generalizability of the findings for 
cla to other populations. 
Study design
In chapter 4, the effect of lactotripeptides was investigated in an 8-week randomized 
placebo-controlled trial. The trial was conducted according to Good Clinical Practice, 
providing quality assurance for the results. The randomization succeeded in achieving 
its goal; relevant subject characteristics (including blood pressure) were balanced over 
the treatment and control groups. The trial was conducted in a double-blind fashion, 
i.e. until data-analysis was completed subjects and research staff remained blinded to 
[a] treatment allocation and [b] all blood pressure values. For safety aspects, a research 
assistant who was not otherwise involved in the conduct of the trial checked whether 
systolic blood pressure did not increase by more than 30 mm Hg compared to a previous 
visit (i.e. pre-defined limit approved by Medical Ethics Committee and collaborating 
general practitioners). This was not the case. 
Effects of cis-9, trans-11 cla on blood pressure (chapter 5) were studied in a 9-week 
randomized cross-over trial with three consecutive periods lasting three weeks each. 
This design allows within subject comparison of the diets containing oleic acid (i.e. 
control), industrial trans fatty acids or cis-9, trans-11 cla. Despite the single-blind 
fashion of this trial, research assistants who assessed blood pressure were unaware of 
treatment allocation. Subjects were not informed about their blood pressure or type of 
diet they consumed until completion of data analysis. Blinding of treatment, however, 
was not completely successful as almost all (96%) subjects recognized one of the three 
diets (industrial trans fatty acid diet) due to the solid margarine. Yet, as blood pressure 
was a secondary outcome and most subjects were not aware of this aim of the study, it 
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is unlikely that awareness of order of the diets would have had a large impact on blood 
pressure values. 
Treatment and compliance
In our trials high doses of lactotripeptides and cla (chapters 4 and 5) were used that 
cannot be achieved by normal dairy consumption. The dose of lactotripeptides which 
we used in our trial (chapter 4) was 14 mg per day. Although the amount of 
lactotripeptides in a normal diet is unknown, our dose was higher than what was used 
in most previous trials on lactotripeptides (2-6 mg per day). Our trial on cla (chapter 
5) contained about 20 grams per day (with an energy intake of 10 mj), whereas a normal 
diet contains approximately 0.3 grams cla per day20, 21. Our trials, however, aimed to 
unravel a possible underlying mechanism for the observed associations between (low-
fat) dairy and hypertension and using these high doses ensured sufficient contrast 
between treatments to observe relevant differences.
Another important issue is the duration of the intervention. In most dietary intervention 
studies, effects on blood pressure (if any) become visible within 4-8 weeks22-24. Hence, an 
8-week intervention with a dose of 14 mg lactotripeptides equivalents (chapter 4) 
should have been sufficiently long for detecting an effect on blood pressure, if present. 
In the multiple cross-over trial on cla (chapter 5), the intervention periods were only 
three weeks. A longer intervention would have been more appropriate, although blood 
pressure changes have been achieved within such a short time period, e.g. in the dash 
trial where blood pressure decreased after two weeks and was maintained for the next 
six weeks22. 
Compliance to treatment is important in an etiological study in which one aims to 
assess the maximal effect of the intervention on blood pressure. In the trial on 
lactotripeptides (chapter 4) compliance was assessed by checking diaries in which 
subjects recorded consumption and time of test products on a daily basis. Additionally, 
empty and full cups that were returned by subjects were counted. Compliance in this 
study was satisfactory; only 4 subjects consumed less than 80% of their provided test 
products. Moreover, only one subject dropped out in week 3 of the intervention for 
personal reasons unrelated to the trial. In the strictly controlled feeding trial on cla 
(chapter 5), subjects consumed their hot meal under supervision at the research center 
and compliance was assessed by checking diaries and measurements of blood fatty 
acids. Diaries kept by the subjects revealed only minor deviations from the protocol and 
the cla proportion in blood fatty acids was 3.1 times higher after the cla diet than 
after the oleic acid diet. Only two subjects dropped out for personal reasons unrelated 
to the trial. 
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assessment of blood pressure
Blood pressure is subject to variation as described previously in this chapter. In order 
to reduce random error as much as possible, standardized protocols (at least 10 minutes 
rest, validated device, appropriately sized cuff) were applied in our trial on 
lactotripeptides as described in chapter 4. Blood pressure was a secondary, though 
prespecified, outcome in the cla trial (chapter 5) and a standardized blood pressure 
protocol was also applied in this study. Strict measurement conditions strongly 
increased the precision with which blood pressure was assessed. Random error, however, 
can never completely be ruled out. This generally leads to wider confidence intervals for 
the blood pressure effect due to treatment, but is unlikely to have affected the internal 
validity of our studies and size of the effect estimates. 
Effects unrelated to the intervention
In our trial on lactotripeptides (chapter 4), the control group also showed favorable 
changes in blood pressure during the intervention period. These changes cannot be 
attributed to the lactotripeptides and other external factors must explain these changes. 
First, as subjects with elevated blood pressure were selected to participate in the trial, 
this effect may partly be explained by ‘regression-to-the-mean’. Second, the measured 
effect might be the result of study participation rather than the result of the intervention. 
Finally, we cannot exclude the possibility that the dairy drink itself (i.e. 200 mL low-fat 
yogurt drink per day) influenced blood pressure. Because the trial was not set up to test 
this hypothesis, the blood pressure effect of the low-fat yogurt remains unknown. 
In our trial on cla (chapter 5), invalid conclusions due to effects unrelated to the 
intervention are not very likely. First, blood pressure was not an inclusion criterion in 
this study. Inclusion of normotensive subjects reduced the possibility of the ‘regression-
to-the-mean’ phenomenon. Second, food intake was largely controlled; 90% of the foods 
were supplied by the university where subjects also consumed their hot meal during 
week days. Intentional dietary changes during the trial are therefore excluded. Third, 
blood pressure was a secondary outcome of the trial and most subjects were unaware 
of this aim of the study. Subjects were not focused on lowering their blood pressure 
during the trial making intentional lifestyle or behavioral changes less likely. Finally, 
the trial was conducted according to a randomized cross-over design meaning that 
subjects were their own control. 
Interpretation and validity of the findings from intervention studies
Previous trials on the lactotripeptides ipp and vpp were rather consistent in showing a 
blood pressure lowering effect (1.5 to 11.0 mm Hg systolic)25, 26, mainly in Japanese and 
Finnish subjects. It should be noted, however, that in some placebo-controlled trials the 
results were reported as changes from baseline within groups instead of comparisons 
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of changes between groups. In addition, in several studies initial blood pressure levels, 
despite randomization, tended to be higher in the intervention than in the control 
group meaning that effects attributed to lactotripeptides may actually have resulted 
from ‘regression-to-the-mean’. In our relatively large trial relevant subject characteristics 
were equally balanced over the treatment and placebo groups. We used a high dose of 
lactotripeptides, different blood pressure measurements, and we measured parameters 
of the proposed underlying mechanism. We did not find a blood pressure-lowering 
effect of the lactotripeptides ipp and vpp. Although we consider it unlikely, we cannot 
exclude that lactotripeptides may exert their effect only in subjects with clinically 
established hypertension. We were the first who published a study with “null” results in 
this field. More studies that could not confirm a beneficial effect of these two 
lactotripeptides on blood pressure or ace inhibition have recently been published27, 28. 
We therefore cannot exclude publication bias in this field of research which is also 
suggested by the meta-analysis by Pripp et al25. 
Little research has been done on cla and blood pressure. Previous studies have focused 
on cla mixtures with a high content of trans-10, cis-12 cla29-31. The trans-10, cis-12 
isomer has been suggested to have more unfavorable effects on health than cis-9, 
trans-11 cla32, 33. Less was known about the effect of cis-9, trans-11 cla. Although 
different effects of cis-9, trans-11 cla on blood pressure might have been expected, the 
results from our study are in line with previous studies on the effects of cla mixtures 
on blood pressure29-31.
How could dairy influence blood pressure?
Dairy foods are an important source of protein and minerals, and high-fat dairy 
contributes significantly to the intake of total and saturated fatty acids in the 
Netherlands4. There are several hypotheses on how dairy may lower blood pressure, but 
the underlying mechanisms remain to be established. A substantial body of evidence 
points to calcium as the main nutrient responsible for a beneficial effect of dairy on 
blood pressure, although the size of effect is relatively small. Meta-analyses of clinical 
trials documented modest reductions in systolic blood pressure of 1-2 mm Hg for 
calcium doses of 400 to 2000 mg/d24, 34-36. Several mechanisms have been proposed on 
how calcium could be involved in blood pressure regulation37, 38. Calcium-regulating 
hormones, e.g. parathyroid hormone could play a role. Calcium is also important for 
vascular smooth muscle contraction, and has been shown to induce natriuresis and 
prevent sodium-induced elevations in blood pressure.
Zemel hypothesized that dietary calcium plays a key role in blood pressure regulation 
in two ways; indirectly by influencing weight management and directly via suppression 
of 1,25-dihydroxyvitamin D, thereby reducing vascular smooth muscle intracellular 
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calcium, peripheral vascular resistance and blood pressure6. Findings from our 
observational analyses do not support an intermediary role of body weight, as discussed 
previously. 
In the us, fortified milk is a main dietary source of vitamin D. A prospective population-
based study by Wang et al. in 28,886 middle-aged us women showed that intakes of 
low-fat dairy products, calcium, and vitamin D were each inversely associated with risk 
of hypertension15. Since vitamin D enriched milk is not available in the Netherlands, we 
lack data to study the added value of vitamin D in dairy products in blood pressure 
control.
In both our observational studies (chapters 2 and 3), we observed an inverse relation of 
incident hypertension with low-fat dairy intake, but not with high-fat dairy. This 
differential association could not be explained by differences in calcium content, since 
that was more or less similar for e.g. semi-skimmed milk (123 mg Ca/100 g) and high-
fat milk (116 mg Ca/100 g).  
In countries where dairy intake is high, it may contribute to one fifth of the total daily 
intake of potassium and magnesium. These minerals have been shown to lower blood 
pressure in randomized controlled trials, with stronger and more consistent effects for 
potassium (2 to 6 mm Hg systolic) than for magnesium (1 mm Hg systolic)23, 39-43. 
Milk contains approximately 3.5% protein, of which ~80% casein and ~20% whey. 
Protein has been inversely associated with blood pressure in several observational 
studies44-46. In the Omniheart trial among 164 prehypertensive us subjects, partial 
substitution of carbohydrate with a mixture of animal and vegetable protein 
significantly lowered blood pressure47. There is some evidence that high protein intake 
may influence body weight and glucose control48-50, which could partly mediate an 
antihypertensive effect. Dietary protein has also been shown to increase renal sodium 
excretion44. Little is known about the specific effect of protein from dairy on blood 
pressure, but an effect on renal function, possibly by interaction with accompanying 
micronutrients (e.g. calcium, phosphorus) in dairy, has been suggested. 
A fair amount of research into the blood pressure lowering effect of protein has 
addressed the ace-inhibiting properties of milk, fermented milk or its peptides25, 26. 
Although ace-inhibiting properties of fermented milk or its peptides have been shown 
in in vitro and animal models51, recent data in human suggest that the plasma 
concentration of ace-inhibiting peptides are far below the effective concentration for 
plasma ace-inhibition52. In our trial, we found no effect of the lactotripeptides ipp and 
vpp on blood pressure, ace-activity and angiotensin ii (chapter 4). More studies that 
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could not confirm a beneficial effect of these two lactotripeptides on blood pressure or 
ace-inhibition have recently been published27, 28. The blood pressure lowering potential 
of milk-derived peptides is currently subject to debate and ace-inhibition in vivo by 
these peptides is getting into doubt.
Up until now, total fat, saturated fat and industrial trans fatty acids have not been 
clearly associated with blood pressure and have therefore not been prioritized as an 
important blood pressure determinant53-57. The role of fats from dairy sources in blood 
pressure regulation is still unclear. Cis-9, trans-11 conjugated linoleic acid (cla), a trans 
fatty acid which is unique for dairy products, has recently attracted much attention 
because of the observed favorable effects on health (e.g. improved insulin sensitivity 
and blood lipid profile) in animal studies32. In addition, cla was found to lower blood 
pressure in several rat models58-60. This could not be confirmed, however, in human 
intervention studies29-31 and chapter 5. On the basis of current evidence, we consider 
dairy fat not a major factor in blood pressure regulation. More research is needed, 
however, on specific types of fatty acids in dairy, including short- and medium-chain 
length fatty acids that are abundant in ruminant milk fat.
Dairy also contributes to sodium intake (i.e., ~15% in the Netherlands). Sodium is an 
established risk factor for hypertension53 and could counteract a potentially beneficial 
effect of dairy. We observed no association of cheese consumption with risk of 
hypertension in the morgen study (chapter 2) and in the Rotterdam study (chapter 3). 
To the best of our knowledge, studies showing a increased risk of hypertension or 
cardiovascular diseases with consumption of cheese have not been published. 
Public health implications 
Nutritional aspects of dairy
Dairy products are considered as nutrient-dense foods which can contribute substantially 
to daily intakes of nutrients such as calcium (~70%), vitamin B2 (~50%), vitamin B12 
(~35%), protein (~25%) and potassium and magnesium (~18%)4. The average intake of 
dairy products in Dutch adults is 2-3 servings per day (~350-400 mL)4, which is below 
the current recommendation of 450-650 mL for milk and milk products61. The Dutch 
Nutrition Center and the Dutch Health Council acknowledge the contribution of dairy 
products to a healthy diet, with special emphasis on the use of reduced fat or skimmed 
alternatives61. In the us a daily intake of 3 servings of (fat-free or low-fat) milk  is 
recommended62, but over the past decades a trend towards consuming less milk and 
more soft drinks has occurred and typical intakes are lower than recommended63. In 
the us as well as in the Netherlands current recommendations are primarily directed 
towards the prevention of osteoporosis by ensuring an adequate intake of calcium. 
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Diet and blood pressure: the role of dairy
Diet and lifestyle are important for maintaining a healthy blood pressure53. In line with 
previous studies on dairy intake and blood pressure, we observed that intake of low-fat 
dairy products may reduce the risk of hypertension (chapters 2 and 3). However, it 
should be noted that evidence has mainly been derived from observational studies, and 
controlled intervention studies are needed to confirm these findings. Although the 
dash trial demonstrated that a healthy diet which includes low-fat dairy products can 
substantially reduce blood pressure, it is likely that this should be attributed to several 
aspects of the dash diet, rather than just one nutrient or food22. 
Based on our observational findings, an intake of 1 serving of low-fat dairy products per 
day seems adequate with regard to blood pressure. We did not observe a ‘dose-response’ 
type of relationship for low-fat dairy. With regard to (very) high intakes of dairy or 
specific dairy foods, there was no evidence for a harmful effect on blood pressure in our 
studies. Even though high-fat dairy products were not associated with an increased risk 
of hypertension, we are of the opinion that low-fat dairy products are to be preferred in 
view of the total cardiovascular risk profile (e.g. blood lipids, weight management). 
Based on the findings presented in this thesis, and evidence from the scientific 
literature, there is at present no need to adapt the current recommendations for milk 
and milk products for the specific purpose of hypertension prevention. 
In both our observational studies the risk of hypertension was reduced by ~20%, 
corresponding to a reduction in systolic blood pressure of 3 mm Hg in a general 
population with an average systolic blood pressure of 126 ± 19 mm Hg. Small reductions 
in blood pressure, if applied to the entire population, could have a huge public health 
impact. A population-wide reduction in systolic blood pressure of 3 mm Hg has been 
translated into a 12% reduction in stroke mortality and a 9% reduction in mortality 
from coronary heart disease64. 
The risk reduction for hypertension that we found for low-fat dairy is in line with 
several other observational studies. Evidence in this field, however, is not yet conclusive 
and more prospective cohort studies are needed, preferably with multiple measurements 
of diet and blood pressure over time. Also, it would be worthwhile to investigate the 
blood pressure effect of low-fat dairy in a well-designed and controlled feeding trial, 
thereby avoiding other dietary changes. If this appears to be successful, a randomized 
controlled trial may also be conducted in an international multicenter setting so that 
the importance of low-fat dairy for hypertension prevention can be studied in 
populations with different habitual dairy intakes, e.g. us, Asia, and Europe. In case a 
beneficial effect of low-fat dairy is confirmed in randomized controlled trials, further 
research into dairy components could be initiated.
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What was already known
•	A	healthy	diet	can	substantially	lower	blood	pressure.
•		Observational	 studies	 suggest	 an	 inverse	 association	 of	 dairy	 intake	 with	 blood	
pressure, but findings are not conclusive.
•		Calcium	is	considered	the	main	dairy	nutrient	that	is	responsible	for	blood	pressure	
reduction, although it has only a small effect.
•		Lactotripeptides	 (ipp and vpp) lowered blood pressure in Japanese and Finnish 
(mildly) hypertensive subjects.
•	Little	is	known	about	the	effect	of	conjugated	linoleic	acid	(cla) on blood pressure
What this thesis adds
•		Low-fat	dairy	intake	may	reduce	the	risk	of	hypertension	by	20%	in	younger	and	
older Dutch adults.
•		There	is	no	evidence	for	an	antihypertensive	effect	of	ipp and vpp in Dutch subjects 
with high-normal blood pressure or untreated hypertension.
•		High	cis-9, trans-11 cla intake is unlikely to affect blood pressure in normotensive 
Dutch subjects.
•		This	thesis	indicates	the	need	for	more	prospective	cohort	studies	and	randomized	
controlled trials on low-fat dairy and blood pressure
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Summary
Blood pressure is a strong, independent and modifiable risk factor for cardiovascular 
and renal diseases. The worldwide prevalence of hypertension is increasing rapidly, 
which calls for effective public health measures throughout the entire range of blood 
pressure. Diet and lifestyle play an important role in maintaining a healthy blood 
pressure. Whether intake of dairy products could play a role in reducing population 
blood pressure remains to be established. The research described in this thesis was 
initiated to further investigate the role of dairy foods in relation to blood pressure in 
the Dutch population. The aims were [1] to examine the association of (specific types 
of) dairy food intake with blood pressure level and incident hypertension in two Dutch 
population-based cohorts (20-65 y and over 55 y of age) and [2] to assess the effect of 
two dairy components on human blood pressure, i.e. lactotripeptides (ipp and vpp) and 
cis-9, trans-11 conjugated linoleic acid (cla).  
Previous observational studies conducted in Europe and the us generally suggest an 
inverse association between dairy intake and blood pressure or hypertension, although 
findings are not conclusive. The Netherlands is a country where a wide variety of dairy 
products is consumed, which allows detailed examination of the association of total 
dairy and specific dairy foods with blood pressure over a broad range of intake. In 
chapters 2 and 3, the association of dairy intake with blood pressure and risk of 
developing hypertension was examined using data from two Dutch population-based 
cohort studies. The average total dairy intake of young and middle-aged adults from the 
morgen study (chapter 2) and older adults from the Rotterdam study (chapter 3) was 
350-400 mL (~2.5 servings) per day, ranging from less than 1 serving in the lowest 
category to ~5 servings in the highest category of dairy intake. Blood pressure level was 
not consistently related with overall dairy intake or intake of specific dairy foods in 
21,553 Dutch adults aged 20-65 y from the morgen study (chapter 2). The risk of 
developing hypertension was examined in 3454 of these participants with 5 y of follow-
up (chapter 2) and in 2245 older Dutch adults from the Rotterdam study with 6 y of 
follow-up (chapter 3). In both studies, the risk of hypertension was reduced by ~20% in 
subjects who consumed more than 150 mL (~1 serving) of low-fat dairy per day. Other 
dairy foods, i.e. fermented dairy, high-fat dairy, milk and milk products, and cheese 
were not consistently associated with risk of hypertension (chapters 2 and 3).
With respect to the blood pressure lowering potential of specific dairy components, 
promising results for milk-derived bioactive peptides (ipp and vpp) have been reported 
for Japanese and Finnish subjects with elevated blood pressure. In chapter 4, the blood 
pressure effect of the lactotripeptides ipp and vpp was assessed in an 8-week randomized 
double-blind controlled trial in 135 middle-aged Dutch subjects with elevated blood 
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pressure. After a 2-week run-in period on placebo, subjects were randomly allocated to 
4 groups who received a daily dose of 200 mL dairy drink with 14 mg lactotripeptides 
obtained by concentrating fermented milk, enzymatic hydrolysis, or chemical synthesis, 
or placebo for 8 weeks, followed by a 2-week wash-out. Blood pressure was not affected 
by intervention with lactotripeptides. The mean difference (95% confidence interval) in 
systolic blood pressure response between the treatment and control group was 2.8 mm 
Hg (−2.6, 8.2) for lactotripeptides obtained by fermentation, −0.5 mm Hg (−6.0, 5.0) for 
lactotripeptides obtained by enzymatic hydrolysis, and 1.6 mm Hg (−3.9, 6.9) for 
synthetic lactotripeptides (p = 0.46). Treatment did also not affect diastolic blood 
pressure, home blood pressure, 24-h ambulatory blood pressure, plasma ace-activity or 
plasma angiotensin ii. Thus, our study did not support the hypothesis of an 
antihypertensive effect of these specific peptides. 
Another dairy component that has recently attracted much attention is cis-9, trans-11 
conjugated linoleic acid (cla). Favorable effects of cla on health, including weight 
reduction, insulin sensitivity, blood lipid profile, and blood pressure, have been reported 
in animal studies. Little is known about the effect of cla in humans. Therefore, the 
objective of chapter 5 was to study the effect of cis-9, trans-11 cla on human blood 
pressure in a randomized cross-over trial. Sixty-one young normotensive Dutch subjects 
were sequentially fed each of 3 diets for 3 weeks, in a random order, for a total of 9 
weeks. Diets were identical except for 7% of energy (18.9 g in a diet of 10 mj/day), which 
was provided either by oleic acid, by industrial trans fatty acids, or by cis-9, trans-11 
cla. High intakes of cis-9, trans-11 cla did not affect blood pressure. The effect of the 
cla diet on systolic blood pressure was +0.11 mm Hg (95% ci: −1.27, 1.49) compared to 
the oleic acid diet. The effect of the industrial trans fatty acid diet on systolic blood 
pressure was +1.13 mm Hg (−0.25, 2.51) compared to oleic acid. 
The main findings, methodological issues and interpretation of the findings of the 
studies described in this thesis are discussed and put into public health perspective in 
chapter 6. In line with previous studies on dairy intake and blood pressure, the 
observational studies described in this thesis support the hypothesis that low-fat dairy 
may reduce the risk of developing hypertension. However, evidence in this field is not 
yet conclusive and more prospective cohort studies are needed, preferably with multiple 
measurements of diet and blood pressure over time. Additionally, well-designed and 
controlled feeding trials are needed to confirm a blood pressure lowering effect of low-
fat dairy, if present. In case a beneficial effect of low-fat dairy is confirmed in randomized 
controlled trials, further research may focus on specific dairy components. With regard 
to dairy components, we conclude that the lactotripeptides ipp and vpp and cis-9, 
trans-11 cla are unlikely to play an important role in blood pressure regulation. 
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Current dietary guidelines in countries like the us and the Netherlands include 2-3 
servings of low-fat or fat-free dairy per day, which is mainly based on the prevention of 
osteoporosis by ensuring an adequate intake of calcium. Based on the findings presented 
in this thesis, and evidence from the scientific literature, there is at present no need to 
adapt these recommendations for the purpose of hypertension prevention. 
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Samenvatting
Bloeddruk is een belangrijke risicofactor voor het krijgen van hart- en vaatziekten en 
nierziekten. Een optimale bloeddruk is een systolische druk lager dan 120 mm Hg en 
een diastolische druk lager dan 80 mm Hg. Van hypertensie wordt gesproken wanneer 
de bloeddruk groter of gelijk is aan 140/90 mm Hg of wanneer antihypertensieve 
medicatie gebruikt worden. Het risico op hart- en vaatziekten en nierziekten neemt toe 
bij elke bloeddrukstijging, zowel bij hypertensieven als normotensieven. Dit begint al 
bij systolische bloeddrukwaarden van meer dan 115 mm Hg (wat geldt als een ‘normale’ 
bloeddruk). Een hoge bloeddruk is een omvangrijk gezondheidsprobleem in Nederland: 
een kwart van de bevolking is hypertensief en nog eens een kwart is prehypertensief. 
Een kleine verandering in de bloeddruk in deze populatie heeft grote gevolgen op de 
volksgezondheid: bij een daling van 5 mm Hg (systolisch) zou het aantal beroerten 
met een derde afnemen en het aantal infarcten met een vijfde. Maatregelen om de 
bloeddruk te verlagen zijn daarom zinvol en gewenst op iedere leeftijd en bij elke 
bloeddrukwaarde. 
Voeding en leefstijl spelen een belangrijke rol bij het handhaven van een gezonde 
bloeddruk. Bij het streven naar een gezonde bloeddruk is het onder meer van belang om 
voldoende te bewegen, een gezond lichaamsgewicht te behouden, zuinig om te springen 
met zout, matig te zijn met alcohol en een gevarieerde en gezonde voeding te eten. De 
consumptie van zuivelproducten is een belangrijk kenmerk van het voedingspatroon 
in de westerse wereld, vooral in Nederland. Er zijn aanwijzingen dat zuivelproducten 
een rol kunnen spelen bij het handhaven van een gezonde bloeddruk. In een aantal 
grootschalige epidemiologische studies (maar niet in alle) wordt een lagere bloeddruk 
gevonden bij toenemende zuivelconsumptie. Of zuivelproducten daadwerkelijk een 
rol kunnen spelen bij het handhaven van een gezonde bloeddruk is echter nog niet 
overtuigend vastgesteld.
In dit proefschrift hebben we de mogelijke rol van zuivelproducten in relatie tot 
de bloeddruk onderzocht in de Nederlandse situatie. De doelstellingen waren [1] te 
onderzoeken of inname van (bepaalde typen) zuivel gerelateerd is aan de hoogte van 
de bloeddruk en het risico op het ontwikkelen van hypertensie en [2] te onderzoeken of 
specifieke zuivelbestanddelen, te weten melkpeptiden (ipp en vpp) en het vetzuur cis-
9, trans-11 geconjugeerd linolzuur (Eng.: Conjugated Linoleic Acid, cla), de bloeddruk 
kunnen beïnvloeden. 
In de hoofdstukken 2 en 3 van dit proefschrift hebben we onderzocht of de zuivelinname 
in Nederland samenhangt met de hoogte van de bloeddruk en het optreden van 
hypertensie. Dit hebben we gedaan in twee grote bestaande steekproeven van de 
129Samenvatting  | 
 
Nederlandse bevolking, namelijk: het morgen project en het ergo (Erasmus Rotterdam 
Gezondheid en Ouderen) onderzoek. In deze cohorten hebben we de gebruikelijke 
zuivelinname vergeleken met de hoogte van de bloeddruk en het ontwikkelen van 
hypertensie over een periode van 2 tot 6 jaar. De gemiddelde zuivelinname van 
deelnemers aan het morgen project (hoofdstuk 2) en ouderen uit het ergo onderzoek 
(hoofdstuk 3) was 350-400 ml per dag wat overeen komt met ongeveer 2 tot 3 porties 
zuivel. Deze zuivelinname varieerde van minder dan 1 portie tot circa 5 porties per 
dag, maar dit verschil in inname was niet duidelijk gerelateerd aan de hoogte van de 
bloeddruk in 21.553 Nederlandse volwassenen in de leeftijd van 20 tot 65 jaar (morgen 
project, hoofdstuk 2). Vervolgens onderzochten we het risico op het ontwikkelen 
van hypertensie in 3.454 van deze deelnemers die gedurende 5 jaar gevolgd werden 
(hoofdstuk 2) en in 2.245 deelnemers van het ergo onderzoek die 6 jaar gevolgd 
werden (hoofdstuk 3). In beide onderzoeken hadden personen die meer dan 150 ml (~1 
portie) magere zuivelproducten per dag gebruikten ongeveer 20% minder risico op het 
krijgen van hypertensie. De inname van andere typen zuivelproducten, bijvoorbeeld 
gefermenteerde zuivelproducten, volle zuivel, melk en melkproducten, en kaas waren 
niet duidelijk geassocieerd met het risico op hypertensie (hoofdstukken 2 en 3).
Met betrekking tot bloeddrukeffecten van specifieke zuivelbestanddelen zijn recentelijk 
veelbelovende resultaten gerapporteerd voor uit melk afkomstige bioactieve peptiden 
(ipp en vpp). Diverse onderzoekers hebben een antihypertensieve werking van deze 
peptiden aangetoond in Japanse en Finse personen met een verhoogde bloeddruk. 
Hoofdstuk 4 beschrijft de resultaten van een interventieonderzoek naar het effect van 
deze melkpeptiden op de bloeddruk bij Nederlandse volwassenen die een verhoogde 
bloeddruk hadden waarvoor ze geen medicatie ontvingen. Op basis van loting werden 
135 deelnemers ingedeeld in vier groepen en kregen gedurende 8 weken dagelijks 
200 ml zuiveldrank te drinken. Drie van de vier groepen kregen een zuiveldrank met 
specifieke melkpeptiden (ipp en vpp) die op verschillende manieren waren verkregen; 
namelijk: door het concentreren van gefermenteerde melk, door enzymatische 
hydrolyse en door chemische synthese. De controlegroep kreeg 200 ml zuiveldrank 
zonder extra melkpeptiden. Gedurende het onderzoek werden allerlei metingen 
verricht waaronder de bloeddruk. De deelnemers wisten tijdens het onderzoek niet in 
welke groep ze zaten en wat hun bloeddrukwaarden waren. Ook de onderzoekers wisten 
niet wie welke zuiveldrank kreeg. Na afloop van het onderzoek bleek dat interventie 
met de zuiveldrank met extra melkpeptiden geen invloed had op de bloeddruk. Het 
gemiddelde effect (95% betrouwbaarheidsinterval) op de systolische bloeddruk was +2,8 
mm Hg (–6,0; 5,0) voor melkpeptiden verkregen door fermentatie, –0,5 mm Hg (–3,9; 
6,9) voor peptiden verkregen door enzymatische hydrolyse en +1,6 mm Hg (–3,9; 6,9) 
voor synthetische peptiden (p = 0,46). De interventie met melkpeptiden had ook geen 
effect op de diastolische bloeddruk, zelfgemeten bloeddruk (thuis, met een geblindeerde 
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bloeddrukmeter), 24-uur ambulante bloeddruk en op concentraties van hormonen van 
het bloeddrukregulerende renine-angiotensinesysteem. Hieruit concluderen we dat ons 
onderzoek eerdere bevindingen van een bloeddrukverlagend effect van deze specifieke 
peptiden niet ondersteunt.
Een andere component uit zuivel dat momenteel in de belangstelling staat is het 
vetzuur cis-9, trans-11 geconjugeerd linolzuur (cla). In dierexperimenteel onderzoek 
zijn gunstige effecten van cla gevonden, waaronder gewichtsvermindering, een 
verbeterde insulinegevoeligheid en een verlaagde bloeddruk. Het is niet duidelijk of 
cla ook dergelijke effecten heeft bij mensen. Het doel van hoofdstuk 5 was daarom 
om het effect van cis-9, trans-11 cla op de bloeddruk bij mensen te onderzoeken. Dit 
werd gedaan in een volledig gecontroleerde voedingsproef, d.w.z. 90% van de voeding 
werd verstrekt door de universiteit, de overige 10% konden de deelnemers zelf kiezen 
uit een lijst van voedingsmiddelen. Een groep van 61 jonge, gezonde Nederlandse 
volwassenen met een normale bloeddruk kreeg achtereenvolgens 3 verschillende 
testvoedingen aangeboden voor een periode van 3x3 weken, in willekeurige volgorde. 
De drie voedingen waren identiek, met uitzondering van 7% van de energie (18,9 g in 
een voeding van 10 mj per dag) die werd verstrekt in de vorm van oliezuur, industriële 
transvetzuren, of cis-9, trans-11 cla. De deelnemers kwamen gedurende 9 weken elke 
maandag t/m vrijdag naar de universiteit om hun warme maaltijd te nuttigen. De rest 
van de voeding (inclusief aanwijzingen voor bereiding) kregen de deelnemers mee 
naar huis. Gedurende het onderzoek werden allerlei metingen verricht, waaronder 
de bloeddruk. Er was geen verschil in de hoogte van de bloeddruk na de diverse 
testvoedingen. Het effect van de voeding met cla op de systolische bloeddruk was +0.11 
mm Hg (95% betrouwbaarheidsinterval: –1,27; 1,49) in vergelijking met de voeding 
die was verrijkt met oliezuur. Het effect van de voeding met industriële transvetzuren 
op de systolische bloeddruk was +1.13 mm Hg (–0,25; 2,51). Een hoge inname van het 
vetzuur cis-9, trans-11 cla lijkt de bloeddruk dus niet te beïnvloeden, in ieder geval niet 
op korte termijn. 
De belangrijkste bevindingen, methodologische aspecten en de interpretatie van 
de bevindingen van de studies beschreven in dit proefschrift worden besproken in 
hoofdstuk 6. Ook de mogelijke betekenis voor de volksgezondheid en suggesties voor 
toekomstig onderzoek komen in dit hoofdstuk aan bod. De resultaten van ons onderzoek 
bevestigen de hypothese dat het gebruik van magere zuivelproducten het risico op het 
ontwikkelen van hypertensie mogelijk kan verlagen. Deze bevindingen moeten echter 
bevestigd worden in andere prospectieve onderzoeken met meerdere metingen van de 
voeding en de bloeddruk in de tijd. Daarnaast is het wenselijk om goed gecontroleerde 
voedingsproeven uit te voeren waarin wordt nagegaan of magere zuivel daadwerkelijk 
de bloeddruk verlaagt. Als het gunstige effect van magere zuivel wordt bevestigd kan 
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er verder onderzoek worden gedaan naar de antihypertensieve werking van specifieke 
bestanddelen van zuivel. Met betrekking tot componenten uit zuivel concluderen we 
dat de melkpeptiden ipp en vpp en het vetzuur cis-9, trans-11 cla waarschijnlijk geen 
belangrijke rol spelen in de regulering van de bloeddruk.
In Nederland wordt geadviseerd om 2 à 3 porties magere of vetvrije zuivelproducten per 
dag te nuttigen. Dit is voornamelijk gebaseerd is op de preventie van osteoporose door 
het waarborgen van een adequate inname van calcium. Op basis van de bevindingen 
van dit proefschrift en de wetenschappelijke literatuur, is er vooralsnog geen reden om 
deze aanbevelingen te wijzigen voor de preventie van hypertensie.
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